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Summary

The Evidence-based Toxicology Collaboration (EBTC) was established recently to translate evidence-based
approaches from medicine and health care to toxicology in an organized and sustained effort. The EBTC
held a workshop on “Evidence-based Toxicology for the 21st Century: Opportunities and Challenges” in
Research Triangle Park, North Carolina, USA on January 24-25, 2012. The presentations largely reflected
two EBTC priorities: to apply evidence-based methods to assessing the performance of emerging pathwaybased testing methods consistent with the 2007 National Research Council report on “Toxicity Testing
in the 21st Century” as well as to adopt a governance structure and work processes to move that effort
forward. The workshop served to clarify evidence-based approaches and to provide food for thought on
substantive and administrative activities for the EBTC. Priority activities include conducting pilot studies
to demonstrate the value of evidence-based approaches to toxicology, as well as conducting educational
outreach on these approaches.
Keywords: evidence-based toxicology, evidence-based medicine, systematic review, validation, test method
assessment

1 Introduction

Formed in 2011, the Evidence-based Toxicology Collaboration (EBTC) is a consortium of stakeholders from academia,
government, and industry promoting the use of evidence-based
approaches in toxicology. The EBTC’s goals are to strengthen
the scientific foundation of toxicological decision making and
to facilitate the continuous improvement of the toxicological

toolbox.1 Guiding principles of the EBTC include transparency,
objectivity, and consistency (Hoffmann et al., in press).
These evidence-based principles and approaches are being
drawn and adapted from the more established field of Evidencebased Medicine (EBM) (Hartung, 2009). EBM pioneered the
use of systematic reviews and similar structured, transparent
approaches to assessing evidence concerning health care interventions. Innovative but sporadic attempts have been made

* Disclaimer: The individual authors do not necessarily represent the views or policies of their institutions nor endorse all
statements herein.
1 http://www.ebtox.com

74

Altex 30, 1/13

Workshop Report

Tab. 1: The four core sessions of the Evidence-based Toxicology Collaboration (EBTC) workshop on
Evidence-based Toxicology for the 21st Century: Opportunities and Challenges
Held January 24-25, 2012 in Research Triangle Park, North Carolina, USA*
Session Topics

1. Pathway Validation

2. Case Studies

3. EBTC Priorities

Presenters

Richard Judson
(US EPA)

Ellen Silbergeld
Suzanne Fitzpatrick
(Johns Hopkins University) (US FDA)

		
		

Daland Juberg
(Dow Agrosciences)

		
		

Patricia Harlow
(US FDA)

Invited Discussants

Robert Chapin
(Pfizer)

Douglas Wolf
(US EPA)

Ed Carney
Kim Boekelheide
(Dow Chemical)
(Brown University)
			
Grace Patlewicz
(DuPont)

Richard Judson
(US EPA)

4. EBTC Governance
John Fowle
(US EPA, retired)

Tim Pastoor
(Syngenta)

Roberta Scherer
(Johns Hopkins)

Olga Naidenko
(Environmental Working
Group)

Rashid Shaikh
(Health Effects Institute)

Michael Holsapple
(Battelle)

Dennis Devlin
(ExxonMobil)

				
				
				

Andrew Rowan
(Humane Society
International)

* The full workshop agenda, which included introductory and concluding presentations, is available online at http://www.ebtox.com.

to apply these approaches in toxicology (e.g., Guzelian et al.,
2005; Navas-Acien, 2006; Griesinger et al., 2009). The EBTC
has taken on the challenge of establishing evidence-based toxicology (EBT) in a more organized and sustained effort.
To jumpstart its efforts, the EBTC held a workshop on “Evidence-based Toxicology for the 21st Century: Opportunities and
Challenges” at the U.S. Environmental Protection Agency campus in Research Triangle Park, North Carolina, USA on January
24-25, 2012. The backbone of the workshop was a set of four
sessions, each kicked off by one or more formal presentations,
followed by invited discussants, and then general discussions
(Tab. 1). The full workshop agenda, which included introductory and concluding presentations, is available online.2
The program reflected a number of the EBTC’s priorities.
First, the EBTC is seeking to apply evidence-based methods to
assessing the performance of emerging pathway-based methods
consistent with the National Research Council (NRC) report on
“Toxicity Testing in the 21st Century” (NRC, 2007). In keeping
with this priority, workshop Session 1 featured a presentation by
Richard Judson on the validation of high-throughput pathwaybased assays (Judson et al., 2013) and Session 3 featured a presentation by Suzanne Fitzpatrick on a potential role for EBT in
21st century validation strategies (see Section 5.1). Similarly,
two of the three presentations in Session 2 addressed fundamental questions relevant to establishing the scientific basis of pathway-based assays – one by Daland Juberg on the challenge of
distinguishing adverse responses in these assays from those that
are adaptive or compensatory (see Keller et al., 2012), and one
by Patricia Harlow on the process of confirming that biomarkers used in these and related assays truly reflect the biology of
interest (see Section 4.1).

A second EBTC priority is establishing an administrative
structure and operational procedures that not only facilitate the
work of the EBTC but also reflect core EBM/EBT principles,
including transparency, continuous improvement, and volunteer
inclusion. This priority was addressed in a presentation by John
Fowle in workshop Session 4 (see Section 6.1).
And finally, Ellen Silbergeld, who gave a presentation in Session 2, provided helpful background information on evidencebased approaches and early attempts to apply them to EBT (Silbergeld and Scherer, 2013).
Given the novelty of evidence-based approaches in toxicology,
the workshop program included ample time for both commentaries by invited discussants and discussion among workshop
participants. To facilitate this commentary, the primary speakers
were asked to circulate their presentations – in the form of white
papers or Powerpoint slides – in advance to the invited discussants. The discussants were free to react to the presentations in
their sessions or to discuss related issues.
The papers associated with the formal presentations in each
of the four workshop sessions either appear elsewhere in this
issue of ALTEX (Judson, 2013; Silbergeld and Scherer, 2013) or
are summarized below, except the one associated with Daland
Juberg’s presentation, which was already in press at the time of
the EBTC workshop (Keller et al., 2012). A science writer was
contracted to take the lead in summarizing the invited commentaries and open discussions for the proceedings, except where
noted otherwise below. The invited discussants and the commentators were given an opportunity to review and offer edits
to the draft summary prior to its completion.

2 http://www.ebtox.com
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2 Background information on Evidence-based
Medicine and Evidence-based Toxicology

Evidence-based approaches have strengthened the scientific
foundation of decision making in clinical medicine and health
care by providing a structured framework for assessing the evidence bearing on healthcare questions. Moreover, such critical
appraisals of past studies inevitably encourage improvements in
the prospective design and reporting of new studies. Evidencebased tools are expected to have a similar impact on toxicology
when appropriately translated from the medical context.
The primary tool of EBM is the systematic review, which includes a variety of steps: framing the question to be addressed
and deciding on how relevant studies will be identified and
retrieved, which studies will be excluded from the analysis,
how the included studies will be appraised for their risk of bias/
quality, and how the data will be synthesized across studies
(e.g., meta-analysis). Such reviews also reflect EBM’s hallmark tenets of transparency, objectivity, and consistency to the
maximum extent possible. In addition, systematic reviews
provide a convenient way for interested stakeholders to gain
a condensed snapshot of the key literature and findings on a
given subject.
Although EBM has earlier historical antecedents, its rise as
a distinct discipline is usually credited to the work and advocacy of Scottish epidemiologist Archie Cochrane (e.g., Mayer, 2004). The term “evidence-based” was coined by Gordon
Guyatt in 1990, and “evidence-based medicine” first appears
in the medical literature in 1992 (Guyatt et al., 1992). The Cochrane Collaboration, named in honor of Archie Cochrane, was
launched at Oxford University in 1993 to promote evidencebased reviews of the clinical medicine literature. By 2011, the
Cochrane Collaboration had more than 28,000 active contributors in more than 100 countries, and the Cochrane Library3 contained more than 4,400 systematic reviews (see commentary by
Scherer in Section 6.2).
The translation of evidence-based approaches from medicine
to toxicology is already underway, at least at the conceptual
level, but this process is only a decade old and still in the formative stage. Guzelian et al. (2005) coined the phrase “evidencebased toxicology” (EBT) and noted its promise in assessing the
evidence that specific chemicals cause specific health effects in
humans. Around the same time, Hoffmann and Hartung (2005)
noted the potential value in translating evidence-based assessments of diagnostic measures in medicine to assessments of
test methods in toxicology. Hartung and Hoffmann went on to
further elaborate the conceptual underpinnings of EBT (Hoffmann and Hartung, 2006; Hartung, 2009) and coordinate the
first international conference on EBT, held in Italy in 2007
(Griesinger et al., 2009).
Hartung later founded the EBTC – the collaboration devoted
to advancing EBT – with several partners.4 For practical purposes, separate Steering Committees were established in the

US and Europe. The EBTC traces its beginnings to a 2010
workshop in the United States on “21st Century Validation for
21st Century Tools,” which featured a session on the potential
for evidence-based approaches to assess the performance of a
new generation of non-animal test methods (Hartung, 2010).
The EBTC formed in the ensuing months and held a kick-off
meeting on EBT as a satellite to the 2011 Society of Toxicology
annual conference in the US. The meeting familiarized the primarily US-based audience with the basic concepts and promise
of EBT (Zurlo, 2011). It was well attended and generated enthusiasm for pressing forward to develop EBT approaches. The
tasks to be tackled included identifying priorities, establishing
work groups, developing a governance structure and work processes as appropriate, and engaging interested stakeholders in the
process. It was decided to jumpstart these efforts by holding an
open workshop.
The March 2011 kick-off event was replicated at the 2012 EuroTox conference for the European branch of the EBTC (Hoffmann, 2012).
Given its genesis at a workshop on validation of new methods, the EBTC has retained a keen interest in applying evidencebased approaches to assessing test method performance.
The launching of the EBTC is timely, as the toxicology literature increasingly invokes EB-related themes or practices such
as transparency in decision-making (Schreider et al., 2010),
systematic and transparent reviews of evidence (Sutton et al.,
2011), synthesis of types of evidence to establish causal inference (Adami et al., 2011), and assessment of bias/credibility
(Conrad and Becker, 2010). We also see practical examples of
the application of evidence-based methodology or terminology
(Woodruff et al., 2011; Abhyankar et al., 2011; Maull et al.,
2012).
Evidence-based approaches provide a means of critically appraising evidence in a manner that is transparent, objective, and
consistent. By contrast, standard toxicological practice still includes narrative (and thus subjective) reviews, non-transparent
weight-of-evidence approaches, inconsistent decision-making
procedures regarding the assessment of the hazards and risk
of individual compounds, and reliance on aged toxicological
methods of unclear performance. These practices compromise
decision making and retard innovation in testing methods. Innovation is hampered further by prevailing frameworks for assessing toxicological test methods (i.e., validation), which are
time-consuming, expensive, and intrinsically biased towards
traditional methods.
To remedy these limitations, approaches have been proposed
that build on EBM methodologies (such as systematic reviews)
and practices (such as those established by the Cochrane Collaboration 5). Unfortunately, attempts at implementing these approaches in toxicology remain uncommon and fragmentary.
The North Carolina workshop provided a forum for EBTC
members and interested stakeholders to offer and discuss toxicological and organizational priorities for the collaboration.

3 http://www.thecochranelibrary.com
4 http://www.ebtox.com

5 http://www.cochrane.org
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3 Workshop Session 1:
The validation of high-throughput
pathway-based assays

would be useful for predicting wildlife effects, as well as the
technical concerns that may prove important, such as how to run
assays for cold-blooded animals, he said.

This session featured a presentation by Richard Judson
(see Judson et al., 2013).

3.2 Invited discussant Ed Carney

3.1 Invited discussant Douglas Wolf

The first discussant was Douglas Wolf, who at the time was
the acting director of the Environmental Protection Agency’s
(EPA’s) Exposure Assessment Coordination Policy division in
the Office of Science Coordination and Policy, which, in turn, is
in the Office of Chemical Safety and Pollution Prevention. This
division is responsible for the Endocrine Disruptor Screening
Program (EDSP). Wolf has since become the Assistant Laboratory Director of EPA’s National Health and Environmental Effects Research Laboratory, which is part of the agency’s Office
of Research and Development.
Wolf raised several points. He noted that the 1996 Food Quality Protection Act has language stipulating that EPA must use
validated methods to determine if a chemical has the ability to
disrupt the endocrine system. In the plan published on the EDSP
website, EPA is proposing a phased process. Initially, the agency is using high-throughput methods to help inform its process of prioritizing chemicals for more detailed testing. The results of the high-throughput assays, together with data from the
agency’s exposure evaluation and other available information,
are helping the agency to determine which chemicals should be
tested initially.
Over time, EPA will begin to replace current methods with
high-throughput assays, Wolf predicted. This will happen after
the agency evaluates the high-throughput methods, is able to
show that they do indeed predict the potential for disrupting the
endocrine system, and can either validate them or build confidence in their use. In the short term, Wolf said it will be easy to
replace current in vitro methods with higher throughput assays.
In the longer term, Wolf predicted that the high-throughput assays will replace whole animal methods.
Wolf suggested that the EBTC consider focusing its validation-oriented efforts on the high-throughput assays that were
purposely designed for robotic systems, because we do not have
experience validating these higher throughput systems. Efforts
to determine how to validate them would constitute the best use
of the EBTC’s time and resources.
Wolf said that the EPA’s goal is to provide a level of confidence in the agency’s testing methods that will assure their
validity to all stakeholders.
Finally, Wolf pointed out that it is important to have cell-based
assays to evaluate a chemical’s impact not only on human health
but also on the environment, such as effects on wildlife. Most
of the focus to date has been on systems based on human cells,
cell lines, and mechanistic considerations, mainly because the
pharmaceutical industry has taken the lead in developing highthroughput assay systems. “We at the EPA are equally concerned
with environment and wildlife as we are with human health, so
all of those are going to be necessary.” The research community
should be thinking about what kind of high-throughput assays
Altex 30, 1/13

Ed Carney of the Dow Chemical Company was the second invited discussant. He noted that some whole-animal-based assays for developmental and reproductive toxicity have been
able to identify unique effects that scientists otherwise would
not have been able to predict. In his experience, however, the
observed effects are mostly seen only at doses that are orders of
magnitude higher than human exposure.
Carney said that his own declining satisfaction with the utility
of whole-animal tests reinforces the need for a new paradigm.
He agreed with Wolf that a prerequisite for moving forward with
high-throughput pathway-based assays is a process whereby all
stakeholders gain confidence in their utility.
Carney argued that the best place to begin using high-throughput cell-based assays is with prioritization. There is a strong
need for increasing the capacity of doing such baseline assessments, given that there is only a limited capacity for conducting
animal-based tests. The throughput (high) and the cost (low) of
the pathway-based assays match the need, he said. Currently,
prioritization is needed mainly for chemicals with very little
data, so in effect, the bar is lower than for other applications
such as risk assessment.
However, Carney cautioned that fitness for prioritization does
not guarantee fitness for risk assessment. We need operating discipline to prevent inappropriate uses, he said. For example, the
post-implantation rat whole-embryo culture (WEC) and the Embryonic Stem Cell Test (EST) are appropriate for embryo toxicity
screening; he noted that the European Centre for the Validation
of Alternative Methods (ECVAM) is careful to use qualifying
language stressing that these cell-based assays are not valid as
replacements for in vivo developmental toxicity tests.
A strong causal connection between altered biology in the
high-throughput assays and adverse apical outcomes is needed
to justify use in decision-making, he said. The strength of this
connection currently varies with different types of cell-based
assays. He offered the examples of the estrogen receptor and
androgen receptor as ones in which both the pathways and the
requirements for adverse outcomes are relatively well understood. The association is weaker for other assay endpoints. Case
examples are needed to establish proof of principles, he said.
A practical challenge is to choose which assays to enter into
validation exercises, he noted. Some are ready; some are not.
Establishing an assay’s suitability for a narrow intended purpose should be relatively straightforward. A harder challenge
comes when moving from single assays to groups of assays that
query pathways. Validation then should shift to evaluating the
predictive value of groups of complementary assays, Carney
asserted.
Carney stressed that it is also important to consider the nature
of industrial chemicals. They often have very general functional
properties that drive their use in commerce, such as surfactants
in cleaning agents. This raises the possibility of confounding
results, such as when a tested chemical denatures a target pro77
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tein. Carney sees value in prioritizing chemicals into two broad
categories – those exhibiting non-specific interactions, such as
membrane alteration, and those known to have specific interactions, such as effects mediated by receptors.
3.3 Invited discussant Grace Patlewicz
(with Richard Becker and Ted Simon)

The third respondent to the Judson presentation was Grace Patlewicz of the DuPont Haskell Global Centers for Health and
Environmental Sciences. She opted to submit a written text for
the proceedings in lieu of having her oral remarks summarized
by the science writer. The text (comprising the balance of Section 3.3.) provides recommendations focused on the paper prepared by Judson et al. (2013) and is a summary of a longer document, “ACC Perspectives on Validation of High-Throughput
Assays Supporting 21st Century Toxicity Evaluation,” prepared
by the American Chemistry Council (ACC) Computational Profiling Workgroup, which she co-chairs with Richard Becker of
the American Chemistry Council.
Everyone recognizes that the means by which data are generated and translated into information for the purposes of chemical
regulation and risk assessment is undergoing a massive transformation. There are many drivers for this shift, including animal welfare considerations, advances in scientific techniques to
rapidly screen substances for biological activities, and the large
number of substances that exist in commerce for which toxicity information can vary to a considerable degree. Advances in
high-throughput technologies, including in vitro cell-based assays and toxicogenomics, show considerable promise in changing the manner in which toxicity testing is performed in the future. However, the framework and context in which these types
of data are evaluated and interpreted for regulatory decisions
also will need to transform. The current validation process to
develop scientific confidence in new methods to predict toxicity,
as described by bodies such as ECVAM, the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), and the Organisation for Economic Cooperation and
Development (OECD), also will need to adapt to encompass the
scenario of batteries of in vitro assays being used to evaluate a
given regulatory endpoint, rather than the current framework of
a single assay replacing a single in vivo test protocol.
To develop scientific confidence in high-throughput assays,
the approach described in the Institute of Medicine’s (IOM’s)
Evaluation of Biomarkers and Surrogate Endpoints in Chronic
Disease – namely analytic validation, qualification, and utilization – warrants consideration. Analytical validation entails
analyses of available evidence on the analytical performance
of an assay. Qualification requires the assessment of available
evidence on associations between the measured biomarker
response and adverse effects. Utilization requires contextual
analysis based on the specific use proposed and the applicability of available evidence to this use. For high-throughput assays such as those in the ToxCast™ program, these steps could
be adapted as: 1) Analytical validation, a consideration of the
performance of an assay or suite of assays; 2) Qualification,
an assessment of the association of the assay with a molecular
initiating event, key event, or biomarker within the mode of
78

action (MOA); and 3) Utilization, a contextual and weight-ofevidence analysis of a specific use of quantitative assay results
based on all available evidence.
With respect to analytical validation, one particularly difficult
issue noted by Judson et al. is how to validate proprietary assays
or those that require extensive robotics. A pragmatic approach
for this validation could be to focus on the core basis of the
assay and conduct either a non-proprietary assay that is complementary to the proprietary assay or to conduct one or more of
the high-throughput assays in a low throughput mode. Neither
proprietary nor throughput considerations should be used as
impediments to robust scientific evaluation. Heuristic methods
will also be important, as will consideration of the combined
assay results – chemicals with established activities can serve as
performance standards, and lack of consistency between assay
results for these chemicals should be a red flag. Cross-laboratory testing may also be addressed by performance standards. This
is a core element of validation that should not be avoided due to
practical difficulties.
Qualification addresses how well the assay results reflect key
events within the mode of action. Qualification will necessarily
need to consider differences in potency and efficacy. It will be
particularly challenging to establish the links between the assay
results, the MOA, dose responses, and adverse effects. It is vital
to understand how results of high-throughput assays relate to
biological response pathways (Bhattacharya et al., 2011; Seed et
al., 2005), especially how the quantitative result from an assay
relates to the transition from an adaptive to an adverse response.
With current understanding, it will be challenging to distinguish
results that represent transient and homeostatic responses from
results that reflect adaptive responses (that may be reversible)
from results that are sufficient to cause an adverse outcome.
Utilization raises the question of what level of scientific confidence is needed for different purposes, whether they be screening, prioritization, hazard identification, or hazard prediction.
Clearly, any evaluation should have the end application in mind
(Judson et al.’s “use case”), rather than conducting a “validation” in vacuo. For example, applying high-throughput methods for priority setting would tolerate greater uncertainty than
the same methods being applied to trigger a risk management
regulatory decision. EBT, Bayesian approaches, or other methods may prove useful in integrating many sources of information to arrive at a quantitative weight-of evidence-assessment.
Furthermore, dosimetry and exposure are key in providing the
appropriate context of how a given test concentration in a highthroughput test system relates to a real life exposure. Use of
high-throughput assay results in lieu of traditional toxicity tests
to support hazard identification or hazard prediction is perhaps
the most difficult stage to address in terms of establishing what
level of correspondence between assay results and key events is
really needed.
Twenty-first century toxicology presents an exciting era for
toxicologists, risk assessors, and researchers. Programs such as
the U.S. EPA’s ToxCast™ exemplify how new technologies can
be exploited to address the challenges of risk assessment. The
challenge remaining will be validation/evaluation and gaining
an understanding of the strengths and limitations of these types
Altex 30, 1/13
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of technologies for specific uses. Scientific consensus among
regulators, regulated entities, and stakeholders will be needed in
order to engender confidence in the use of high-throughput prediction models and results for decision-making. Consensus may
be achieved by application of a scientifically sound validation
framework coupled with transparency (data and algorithms)
and responsible communication. Appropriate peer review, communication, and outreach are of paramount importance to the
successful implementation, acceptance, and use of these new
technologies by all stakeholders.
3.4 Open discussion

After the floor was opened for questions, John Fowle, a member
of the US EBTC Steering Committee, asked if there was a way
to inspire companies like Dow or DuPont to share their in vitro
and in vivo discovery data on adverse outcomes to help improve
Quantitative Structure Activity Relationship (QSAR) models.
Carney responded that his company (Dow) was exploring new
approaches to bringing novel chemicals to market and integrating
QSAR data. “We are quite interested in working with government
agencies, particularly EPA, to look at different ways of getting
new products approved,” he said. He said that Dow is currently
involved in a project associated with greener and less hazardous
substitutes, which uses some newer tools, such as in vitro assays
and zebrafish embryos, as well as computerized structure activity
relationship (SAR) analyses of structurally similar analogs for
which existing data might already be available.
Carney said that this project might eventually become a prototype for a different approach to producing the Pre-Manufacture Notifications that companies must submit to EPA to comply
with the Toxic Substances Control Act. In place of guideline
data for, say, fish acute toxicity, it might be possible to substitute
a zebrafish embryo screen and SAR analysis, he suggested.
Wolf sketched an interactive approach to testing that could
inspire chemical and pharmaceutical companies to share their
discovery data. He drew an analogy to companies developing
open-source software applications. Many such applications are
available that people can download for free; users can offer suggestions for improvements. The software’s originator then can
capitalize on the suggestions to make a profitable product. He
argued that this kind of interactive approach would help amass
important data for improving QSAR models.
Errol Zeiger, an independent consultant, argued that data
used to make decisions about the tests or test programs should
be available to other people in case they want to do their own
analyses. He added that high-throughput assays will be a success or failure based on the individual tests used as screening
tools, where the false-negative rate plays a crucial role, but can
rarely be assessed.
Judson pointed out that every false-positive screening test result can force a chemical company to spend half a million dollars to conduct a full battery of tests to prove that its chemical is
actually not problematic.
Thomas Hartung of Johns Hopkins University commented
that EBT is a new toolbox that needs to be evaluated. The beauty
of the evidence-based approach is to transparently define a process before you do it, thereby increasing objectivity, he stressed.
Altex 30, 1/13

Mel Andersen of the Hamner Institutes for Health Sciences
said that the most important information is what are we doing
and why are we doing it – in other words, in how a problem
is defined. He asked Judson if all of the assays being used to
identify modes of action were really required to effectively
identify them.
Judson replied that for any given context, there is a “sweet
spot” – not too many assays and not too few. He also noted the
importance of assessing a test’s fitness for purpose in terms of
balancing its sensitivity and specificity to meet the test objective. Screening tests should be relatively sensitive and specific,
although he acknowledged that it is hard to have both; cost is also a factor. In any case, the purpose is not to say that a chemical
is likely to be, say, positive in a guideline assay, he stressed.
Carl Westmoreland of Unilever, chair of workshop Session
1 and a member of the EBTC’s European Steering Committee,
commented that transparency was an issue that cropped up more
than once in the discussion. Ellen Silbergeld of Johns Hopkins
University explained that transparency has acquired a particular meaning from its association with the Cochrane Collaboration for evidence-based medicine and health care (EBM/HC).
That definition is incompatible with the idea that information
can be shared on a “need-to-know” basis, she said. As defined
by Cochrane, transparency is an absolute condition, Silbergeld
stressed. Because the concept of transparency is fundamental
to EBM, Silbergeld contended that it must also be a key tenet
of EBT.
Wolf responded that an evidence-based assessment of test
method performance requires access to sufficient information
to make a determination about the relevance, reliability, and fitness for purpose of a given assay or set of assays that are being
incorporated into a test method. This begs the question of how
one determines that the amount of information is sufficient to
make a scientifically defensible determination that a given test
method is validated or validate-able; the answer may need to be
determined on a case-by-case basis.
Roberta Scherrer of the Cochrane Center at Johns Hopkins
University pointed out that her center’s focus on transparency is
driven by the goal of ensuring that all systematic review findings
can be replicated. The organization has a publicly available protocol for how to synthesize evidence to ensure transparency.
Patlewicz suggested that the approach the OECD is using
for characterizing QSAR methods could be considered a useful
framework for considering the level of information required to
establish a given assay’s suitability for purpose. She lauded the
framework for its discussion of measures of robustness and how
it defined its domain of applicability.
Maurice Whelan of the European Commission noted that
ECVAM came up with the concept of performance-based test
guidelines to help ensure that the agency was not “embarking
on an endless series of tests.” The guidelines come into play in
instances where two tests have essentially similar components
that are intended to determine the same biological outcome.
Once performance methods have been defined to establish reproducibility, capacity, and accuracy, they can be applied to all
of the methods aimed at that outcome. Performance standards
also can be used to help guide test developers on how to imple79
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ment different versions of essentially the same assay on different platforms, Whelan said.
Performance standards may prove very helpful in the early
stages of implementing high-throughput testing methods, Wolf
commented. They hold promise for targeting peer-review to
whatever a given assay is intended to accomplish, as well as what
a validation process is intended to achieve. Because the assays
are being used as part of a constellation meant to help provide
decision support, they will continually evolve and be replaced.
Performance standards could avoid the need to re-validate every
time a method or assay is replaced by an improved version. Such
an approach also would allow for transparency, he said.
Session chair James Freeman of ExxonMobil characterized
what we’re talking about with EBT as a shift from validation to
“fit-for-purpose.” We’re all steeped in the validation model, but
maybe there is a way to get out of the validation box and move
to fit-for-purpose, he said.
Carl Westmoreland noted the difficulty in judging when an
assay has relevance for a toxicity endpoint or pathway of interest. The issue is tied up with the relevance of the test itself, the
cell line you are looking at, and the concentrations that you are
testing. He invited participants to weigh in on how relevance
could be judged in such cases.
Judson responded that relevance is where test assays will pass
or fail. Today we can run a set of assays with a set of chemicals
for which we have in vivo data, and we can find correlations.
The biology makes sense. The difficulty is to step beyond that
to suggest that correlation is causation. It is hard to support a
claim that the output from many of the new technologies with
different cell types, such as pathway modeling, virtual tissue
modeling, orthogonal assays, and sandwich assays, really is telling you something definitive about what is going to happen in
the animal, he said.
Traditionally, toxicologists are trained to think of “relevance”
mainly in terms of the ability to predict a type of gold standard,
Hartung said. Such a gold standard does not always exist. However, a crucial part of validating a given test is assessing its scientific basis. It is a type of relevance that the current validation
paradigm does not exploit, yet it is exactly the kind of relevance
needed to establish novel assays. We need to model pathways
that are shown scientifically to be relevant for a hazard we want
to study, he said.
This is where the objective and transparent assessments possible with EBT can come into play, Hartung continued. When we
can show that a scientifically sound pathway has been demonstrated, then we have the criteria we need to justify the use of an
assay or group of assays. This is the beauty of a different type of
system. We should think not about being empiric by reproducing data from another type of test system, but by being scientific
by demonstrating that we reflect the science as we know it with
the tools of science and by the scientific method, he said.
Whelan pointed out that the process everyone struggles with
is chemical selection. Because there are so many competing criteria for selecting reference chemicals, he argued for the value
of having many sets of reference chemicals to use to challenge

high-throughput tests in terms of their predictive capacity. He
asked about how the tools of EBT might be used to facilitate
the process of determining what types of references toxicologists should strive for – and how to select chemicals to use as
references.
Some of the questions that people have posed may be ones
that EBT is not designed to answer, Silbergeld said. She likened
EBM to a court of law. EBM does not determine who is guilty
and innocent. It provides the rules of process, such as which information is admitted into the discussion and to the judgment
process. EBT, “if it is following that same path, will do the same.
It provides a set of methods that allow you to reduce bias in terms
of scanning the fact landscape and presenting the information in
a fully transparent method so everybody can replicate the process – not the experiments – by which you identified the outcome
by passing it through evaluatory filters. It is not going to say that
this is more relevant than that. It will say that this is less biased
information that can be utilized in reaching your judgment.”
Hartung explained how EBT might aid in solving the problem
Whelan posed about compiling a list of reference compounds.
An evidence-based approach would be to define the process of
compiling a list of reference compounds, to define the substances to be considered, the criteria to be applied. Before being executed, the process would be peer-reviewed. All the stakeholders should agree that this is a fair way to identify the substances.
This is a way of describing a process that can be reconstructed,
which makes sense to somebody on the outside, and which does
not require the involvement of a “pope.”
Becker pointed out that one of the areas that are going to be
most challenging is prediction modeling. He said that he could
readily see how one could construct a prediction model using
the EBT approach. To create a model, you would take the elements of the assays, an element of exposure and concentration, and other relevant data and knowledge of the substances.
Then evidence-based approaches could be used for assessing
the quality and reliability of the data, and then they could be
plugged into the model. “That, to me, is the process we should
focus in on as a good case study to begin the discussion of the
application of [EBT],” he said, concluding the session.
4 Workshop Session 2:
Case studies

This session featured presentations by Ellen Silbergeld (see
Silbergeld and Scherer, 2013), Daland Juberg (see Keller et al.,
2012), and Patricia Harlow (see Section 4.1).
4.1 Biomarker Qualification at the US FDA Center
for Drug Evaluation and Research 6

Patricia Harlow of the U.S. Food and Drug Administration’s
(FDA’s) Center for Drug Evaluation and Research (CDER)
gave an overview of the process that her center uses to qualify
biomarkers, which they define as objectively measured characteristics that are an indicator of biologic processes (normal or

6 This section is based on a paper prepared for the proceedings by Patricia Harlow.
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pathogenic) or a pharmacologic response to a therapeutic intervention (Biomarkers Definitions Working Group, 2001). The
goal of biomarker qualification is to improve the efficiency of
drug development by achieving a consensus across CDER on
the interpretation of biomarker measurements used in drug applications. Historically, biomarkers have come into common use
in an unstructured manner as the result of many separate studies
published in the scientific literature over many years. A formal
process for the qualification of biomarkers should reduce the
use of animals by eliminating redundant studies conducted by
sponsors who seek biomarkers for common purposes, particularly for safety. Such a process is likely to be more efficient and
transparent than qualifying biomarkers on a case-by-case basis.
The end result of CDER’s biomarker qualification is a conclusion that the biomarker results within the stated “context of use”
can be relied upon to have a specific interpretation and application in drug development and regulatory decision making. Although a biomarker (i.e., the substance or analyte being measured) can become qualified, this qualification is not equivalent
to approval of a specific test or diagnostic device for performing the measurement. Different assays can be used to measure
a single biomarker as long as each assay has been demonstrated
to measure the same analyte, and each assay has been appropriately validated. Once a biomarker is qualified, it can be used in
the qualified context in drug applications. However, the use of
a qualified biomarker depends upon the absence of 1) serious
study flaws in collecting data, 2) application of the biomarker
outside the qualified context of use, and 3) any new scientific
evidence that conflicts with prior conclusions.
CDER initiated the development of its qualification process
with a pilot program that involved two submissions for urinary
biomarkers of nephrotoxicity in rats. The first pilot submission
made by the Predictive Safety Testing Consortium (PSTC) in
2007 resulted in qualification of seven urinary biomarkers in
2008. The second pilot submission made by the International
Life Sciences Institute (ILSI) / Health and Environmental Sciences Institute (HESI) Nephrotoxicity Working Group in 2008
resulted in qualification of two urinary biomarkers in 2010. One
biomarker was qualified in both groups. Based on experience
with these pilot submissions, a formal biomarker qualification
process was proposed and approved by the CDER in 2009.
The framework for qualification of biomarkers and other drug
development tools (DDTs) is provided in a CDER draft guidance on DDTs released in 2010 (US FDA, 2010). This guidance
discusses two types of DDTs, biomarkers and Patient Reported
Outcome instruments, and it describes the process of working
with CDER as well as a process for consistent scientific evaluation. An appendix to the guidance will be issued for each DDT
qualification. This process involves publication of a notice of
qualification in the Federal Register and posting of the qualification letter on the CDER website.
The guidance on DDTs does not discuss evidentiary standards for qualification. The evidentiary standards (the type and
amount of data) needed to support qualification of a biomarker
will vary depending upon the specific proposed context of use.

For instance, a safety biomarker whose proposed context of use
includes multiple test animal species used for toxicology studies
could not be qualified with data obtained only in rats. Furthermore, the evidentiary standards for biomarkers with a clinical
context are expected to be different from those biomarkers with
a nonclinical context of use.
Evaluation of biomarker qualification submissions involves
CDER personnel who are common to all submissions, as well
as personnel who are specific to that particular submission. The
process of qualification within CDER consists of two phases:
a consultation and advice phase and a review phase. The end
result is that the biomarker is either qualified or not qualified in
the stated context of use, and the review is considered complete.
The qualification letter is posted on the CDER website.7 Further description of the qualification process is provided at the
CDER website and in the paper by Woodcock et al. (2011). The
biomarker qualification program is designed to support development of DDTs but, at the same time, to minimize burdens on
CDER product review divisions, whose primary responsibility
is the evaluation of data supporting applications for drug development and drug marketing.
Currently, eight urinary biomarkers for nephrotoxicity in rats
have been qualified by the US FDA, as well as by the European
Medicines Agency. The submissions for these nephrotoxicity
biomarkers contained study reports for rat toxicology studies
that were primarily dose-response studies for multiple nephrotoxicants, as well as some non-nephrotoxicants. Using pooled
data, the diagnostic performance of these biomarkers was evaluated in comparison with currently used nephrotoxicity markers
(blood urea nitrogen [BUN] and serum creatinine) using receiver operating characteristic curves. The reference standard was
histopathology of the kidney. The data indicated that these urinary biomarkers could either outperform or add value to BUN
and serum creatinine in detecting certain drug-induced kidney
lesions (Dieterle et al., 2010a; Harpur et al., 2011; Hoffmann et
al., 2010; Ozer et al., 2010; Vaidya et al., 2010; Yu et al., 2010).
Some evidence supports the utility of these qualified biomarkers
to detect injury in specific nephron segments in the rat. Changes
in urinary kidney injury molecule-1 (KIM-1), clusterin, albumin, trefoil factor-3 (TFF-3) were associated with injury to the
proximal tubule. Changes in urinary cystatin C, total protein,
and β2-microglobulin were associated with glomerular injury.
Changes in urinary clusterin were associated with injury to the
distal tubule. Changes in urinary renal papillary antigen-1 were
associated with injury to the collecting duct.
These qualified renal biomarkers can be used to facilitate drug
development, as illustrated by decision algorithms such as those
presented in Dieterle et al. (2010b). If a drug induces renal histologic lesions in rats but has no effect on the levels of BUN and
serum creatinine, the sponsor could evaluate whether appropriate novel urinary biomarkers are diagnostic of the renal injury
induced by the drug in rats. If the biomarker signal correlates
with the evolution and reversibility of the histologic lesion, the
biomarker would be considered diagnostic of injury in rats and
could be used in defining the no adverse effect level (NOAEL)

7 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/default.htm
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and the starting dose of the drug for first-in-man clinical studies.
If a human assay is available for the particular biomarker, the
sponsor could propose to monitor the biomarker in the clinical
trial. If the biomarker was not diagnostic of injury in rats, then the
proposed clinical trial could be delayed or a higher safety margin
(lower starting dose) would be needed to initiate the trial.
A search of the CDER electronic document database provides
evidence that the qualified urinary biomarkers are being used
in drug regulation. Documents were obtained with reference
to the qualified urinary biomarkers in regulatory reviews and
other documents finalized from 2006 through mid-July 2011.
Based on the number of documents obtained for each biomarker, the documents referring to KIM-1, clusterin, or cystatin C
were examined in more detail. The number of regulatory documents with references to these biomarkers increased after 2008,
the year the biomarkers were qualified. Although references to
these biomarkers were found in documents from all divisions
within CDER, two divisions (Division of Cardiovascular and
Renal Products and Division of Metabolic and Endocrine Products) have produced the largest numbers of documents with
references to these biomarkers. The references to the qualified
biomarkers were found not only in reviews but also in communications with sponsors, such as meeting minutes and advice
letters. Therefore, these qualified nephrotoxicity biomarkers are
being used in CDER regulatory activities.
In addition to the qualification of nephrotoxicity biomarkers,
cardiac troponins were qualified for nonclinical use on February 23, 2012 based on a submission summarizing the publicly
available literature and CDER’s experience with the clinical and
nonclinical use of cardiac troponins. Of the submissions still in
the qualification process, one submission is nearing the end of
the review phase, and fourteen submissions are in the consultation and advice phase. Some of these submissions are for clinical biomarkers. The experience obtained thus far is being used
to refine the process of qualification by formalizing written policies and procedures within CDER. Hopefully, a refined qualification process, as well as the qualification and use of biomarkers, will facilitate efficient drug development of an increasing
number of safe drugs.
4.2 Invited discussant Kim Boekelheide

Invited discussant Kim Boekelheide of Brown University, a
member of the US EBTC Steering Committee, observed that the
EBTC is intending to focus primarily on assessing alternative
test methods, techniques, and tools for analyzing toxic effects,
rather than considering the toxic effects of chemicals per se.
Boekelheide rhetorically asked attendees if they can identify
an approach that the scientific community is likely to agree upon
for taking the new kinds of information being generated via 21st
century toxicity testing assays and translating those into safety
prediction for humans. The key issues have been raised before
in the Toxicity Testing in the 21st Century report (NRC, 2007)
and other forums, Boekelheide said. For example, what do we
do about metabolism and QSAR databases in this new setting?
What are the platforms that are useful and informative? How
do we factor in important information such as human genetic
variability and epigenetics? What computational tools can be
82

used to generate systems biology pathway models based on the
in vitro signals that we identify so that they can be understood in
the context of the larger biology? How do we translate from the
in vitro concentration that we are using to an expected in vivo
exposure, and how do we make these predictions?
Boekelheide also asked attendees if they felt that EBT has a
role in defining what these components and modules are, as well
as what the process is. Does EBT provide a first step in framing
the structure that helps us find a way to make these new assays
work for developing information that we consider to be informative and relevant for humans? This is a different question than
asking whether an assay works, he pointed out. It is pondering
the structure required for all of the different kinds of techniques
that we require in order to make extrapolation work. Is there a
process we as a community can agree upon that culminates in a
larger sense of what that structure needs to be, he asked.
The sources of information for setting up our analysis of these
structures, as well as the particular assays that will support them,
include scientific articles and databases, Boekelheide continued.
In general, there are very few scientific articles published in this
area, which raises the question of what to do in the absence of
information from published sources.
One potential source, Boekelheide said, is the large databases
that now serve as repositories for information collected by new
testing methods; these are growing by leaps and bounds. If you
publish an article that uses a microarray approach, most journals
require you to dump all of that microarray data into a publicly
accessible database, he noted. The question is what to do with
the huge amounts of freely accessible data now available. Is it
the job of an evidence-based toxicologist to use that kind of
information, he asked. If so, who gets paid to make use of what
and how is it used?
Another issue Boekelheide raised is the fact that, unlike the
medical field, there is currently very little commonality for collectively assessing information in toxicology. Every published
paper is likely to use a different cell line, a different platform, a
different array approach, and/or a different species from which
the cell was derived, he lamented.
One possibility for integration is to take the pathways approach, Boekelheide said. Biological pathways and toxicity
pathways are common across species, although there will of
course be differences in details. But this interpretation relies on
an assumption that he predicted will be Sisyphean to prove, that
pathways will be the same and coherent.
Another key issue is how to ensure that the evidence-based
approach will provide the appropriate level of detail to be informative about the information being generated. He viewed the
case studies presented in the workshop session in question as
lacking detail about some important data, such as the quality of
the messenger RNA, which is going to strongly influence the
signal integrity that one gets out in these platforms, he said.
Boekelheide also asked participants to consider whether evidence-based approaches can serve to guide the field prospectively as it designs new assays and tools, rather than simply be
applied to the assessment of previously generated data.
Boekelheide concluded on a hopeful note by suggesting the
evidence-based approach may allow bioinformaticians and statAltex 30, 1/13
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isticians to systematically mine the large amounts of microarray information now in the public domain. This may allow the
information to be manipulated, integrated, and understood in
ways not previously possible.
4.3 Invited discussant Robert Chapin

Robert Chapin of Pfizer – a member of the US EBTC Steering
Committee – speculated about how EBT would look in practice. One area where it may have promise is in comparing assays such as those for estrogenicity reporters. The existence of
only 5 or 10 estrogenicity reporter assays suggests that there is
a reasonable “substrate” for an EBT kind of approach for, say,
identifying performance criteria, he said.
Because Chapin works in developmental toxicology, he said
he has hoped EBT will be able to have an impact in that field.
However, he noted that in the last 10 years, only 10 to 15 papers have reported on purported improvements on some variant of assays using zebrafish, whole embryos, and/or stem cells.
This may violate one of the fundamental operating criteria of
evidence-based approaches: that there should be a sufficient
number of papers out there that all look at the same method and
come up with x, y, or z performance characteristics to allow
them to be compared, he said.
In this regard, Chapin asked Scherer (of the Cochrane Collaboration) how evidence-based medicine handles situations where
there are not enough papers using the same method. She noted
that Cochrane has an “empty” category; that in itself is a finding
because it says that there is no evidence for a given question.
She also pointed out that the Cochrane process evaluates medical evidence for heterogeneity. If the amount of heterogeneity is
deemed critical – which she thought could be analogous to the
situation Chapin described – the process stipulates that the data
cannot be combined analytically. However, the Cochrane process
does allow for a “narrative” review in such situations, whereby
the results from the studies can be presented thematically.
Many of the papers that scientists may want to assess together
will take the form of gene analysis reports, Chapin continued.
Maybe one of the most valuable contributions that an EBT
group could provide would be to encourage statisticians, modelers, and bioinformaticians to dive into the data and analyze them
for commonalities. They may be able to find a new common
denominator across studies that initially appear to have none.
Chapin concluded that the weakness of the evidence-based
approach for some areas of toxicology is that there may not be
enough similarity in the reports in the literature to start the process, a concern mentioned by Boekelheide. To get around this
potential stumbling block may necessitate having experts comb
through the huge volumes of available array data to bring commonalities to light.
4.4 Invited discussant Richard Judson

Richard Judson of the U.S. EPA, a member of the US EBTC
Steering Committee, was the third and final discussant. He acknowledged that coming into this meeting he did not perceive a
difference between EBT and validation. He said that the meeting had made clear to him that validation could be one of many
focal points of EBT.
Altex 30, 1/13

Judson discussed his thoughts on how an evidence-based approach might be used to develop a prioritization program like the
U.S. EPA’s EDSP, a program that Wolf had discussed earlier (see
Section 3.1). It would start with the hypothesis that chemicals
to which people, fish, or frogs are exposed trigger perturbations
to specific pathways. Because we believe that these pathways
could lead to adversity, we want to test these triggering chemicals sooner rather than later. The next step is to look for evidence
linking the pathways to perturbations or adversity. An evidencebased approach can be used to evaluate this. However, you need
to make certain that the exposure is relevant and that the pharmacokinetics are evaluated, he said. Only if the exposure, pharmacokinetics, and pathways come together in an appropriate way
can you get all the way from exposure to adversity.
There is currently a paucity of data for evaluating this, Judson
said. We do have exposure measurements, some incidence information about what is in the nation’s waterways and air, some
chemical use information, and details about how much is manufactured. We have some information about fate and transport
properties, and we can ask if they are similar to chemicals that
we already know a lot about. We also know that some of these
chemicals have endocrine effects. These are all classes of information that we can throw into this process, he said.
Many datasets are available for use as sources of unbiased
data, such as the ACTOR and PubMed, Judson said. EPA’s Integrated Risk Information System (IRIS) assessments for priority
pollutants dataset, which constitute the gold standard for evaluating chemical toxicity, may be amassed via an evidence-based
process, he noted. However, because we have at least 10,000
chemicals that we need to deal with, the IRIS would not be usable to evaluate them quickly enough because the tests take so
long to be completed.
Judson’s comments led to a discussion about EBT’s utility that
many conference participants said they found helpful. Chapin
observed that, with EBT, scientists could evaluate, for example,
whether a method does a good job of identifying in vitro biological activity, and if the findings are transferable across labs. It
could be used as a process for evaluating methods, he said.
4.5 Open discussion

Thomas Hartung explained that evidence-based approaches are
a certain toolbox that can be applied, in principle, to any type of
scientific question. It is a way of condensing information with
criteria that are transparent, objective, and explicit. It requires
tools that have not yet been developed in the context of the new
toxicology. So EBT could address any question in toxicology
– a method evaluation, condensing information on a given substance such as arsenic, a medical treatment problem in clinical
toxicology, etc.
One thing that makes EBT different is that the question is
very clearly defined, he explained. Usually it is a limited, very
precisely defined issue for which all relevant studies are collected. EBT is also different in that the process, not the content,
is in the foreground. It is about constructing a process that is
judged to be the best one possible at the time it is created. Ideally, the process itself is peer reviewed in advance to ensure that
it is sound.
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EBM also involves tools that are not generally used in toxicology, Hartung continued. These tools are used to address the
quality of the data. It also includes formal mechanisms for condensing information.
Finally, there is a mechanism for making the information
available so it is considered to be a resource of highest possible quality. Hartung expressed his hope that, in time, the EBTC
would achieve a quality similar to that of the Cochrane Library,8
which is known to use a rigorous process to ensure that all of its
data is of very high quality. In this way, EBT holds promise for
providing a higher quality than journal peer-review, which can
vary depending upon who is tapped as a reviewer, Hartung said.
What EBT is can change over time, just as EBM has changed
and expanded over the years to become Evidence-based Health
Care (EBHC), Hartung said.
Silbergeld reiterated an analogy from her presentation, comparing EBT to a court of law. There are rules of evidence that
guide how information can be presented to the court. Rules of
evidence do not tell the judge what to decide, she stressed. What
rules of evidence do, and their value, is in imposing order on a
chaotic world of things that present themselves as facts.
The process begins with coming up with some criteria as to
what are relevant, perhaps some key words, which would inform how you would extract the information in question from
the databases where it can be found. Then you amass all the
available data – say, 1260 studies on arsenic. From there, you
apply criteria that determine whether or not you will go any
further with some of the elements that came up in your search,
perhaps study size, a specific type of cell, etc. The end result is
your collection of evidence.
Next, you assess the amassed material for aspects that increase your confidence in the findings. The evidence, with all
its bumps and shining stars, is presented in the most transparent
way possible. You want to have a way to compile the output,
which could take many different forms, such as an odds ratio or
a magnitude of change over a range of exposures, etc. This gives
you a way to weigh the evidence, she explained. Then and only
then can experts come in and make a judgment about what the
evidence suggests.
Scherer added that the Cochrane Collaboration does not provide guidance as to how the evidence amassed by the process
is to be used. It is up to the healthcare providers, insurance
companies, consumers, and other interested parties to look
at the evidence in the context of a specific patient and decide
whether the evidence can be appropriately applied. “We do not
make the judgment; we simply say here is the evidence,” she
explained. The evidence does include conclusions about its reliability and the confidence that the Cochrane Collaboration
has in the results.
Silbergeld stressed that EBT would in no way replace the
wisdom of everyone assembled at the workshop. “The expert
judgment, experience, and wisdom of toxicologists and others
involved in the endeavors we’re all sharing are infinitely valuable,” she said adamantly. What Cochrane does is separate the
process of collecting the information from those making judg-

ments about it. In this way, Silbergeld argued that it is preferable to the current approach taken by the agencies charged with
shepherding toxicology data.
Hartung added that a lot of this is about condensing information so that it can be digested by the scientific community. As an
example, he pointed out that ToxCast data is particularly useful
for identifying toxicity pathways. EBT is useful for comparing
how the ToxCast data identifies such pathways with ones identified via other methods, such as the Hamner approach using case
studies.
The initial utility of EBT will be to build confidence with the
public and stakeholders that what you are doing is relevant for
decisions that are going to have great impact, Silbergeld said.
Rashid Shaikh of the Health Effects Institute expressed concern that the term “evidence-based” could be perceived as offputting, given that scientists already see their work as evidencebased. He said that he perceived utility for EBT but also noted
that implementing it will have its attendant challenges. For example, he foresees the possibility of narrowing down the subject
of interest so much that the result is a filter so fine that not much
comes out of it.
Silbergeld responded that it is possible to explicitly relax a
filter if it becomes clear that it is allowing too few things to pass
through. She added that she became an adherent of EBT due to
her recognition that adopting it could have a positive impact on
the scientific process. Cochrane has improved the practice of
clinical trials enormously, she noted. The British Medical Journal also published a document detailing its utility for environmental and observational epidemiology.
Hartung said that a validation study is for EBT what a multicenter, randomized clinical trial is for EBM. In other words, it
provides the most valuable information, he said. EBT teaches
its adherents about how to set criteria to identify and thus, indirectly, how to produce high quality data.
Chapin noted that what the group is groping toward is a process and trying to find what the process will look like for hauling
together the pieces of data that will be allowable in discussing
whether a test method is appropriately delivering what its developers say that it does.
Silbergeld stressed that framing the problem is key.
Errol Zeiger, a consultant, voiced his developing understanding that EBT can be applied to data regardless of whether it results from a new technology or an old technology. “We’re talking about how to deal with data to evaluate a situation, answer
questions, and recommend decisions,” he said. Many workshop
participants indicated their assent to these comments.
George Woodall of the EPA’s National Center for Environment Assessment (NCEA) noted that his division is in charge
of the IRIS assessments for priority pollutants, and many of the
recommendations made during this session echo those made by
the National Academy of Sciences for the IRIS assessment on
formaldehyde. Those things are being integrated into IRIS, he
noted.
Nicole Kleinstreuer from the EPA’s National Center for Computational Toxicology (NCCT) said that her center initially

8 www.thecochranelibrary.com
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identified the assays used to produce ToxCast data by using an
EBT type of approach. Those assays come from a huge range of
different platforms, including complex cell cultures, human primary cells, zebrafish, and stem cells. Each platform is subject to
rigorous quality control and quality assurance. In a way, we are
really trying to build up our body of evidence, she said. Kleinstreuer works closely with the predictive modeling project, and
she is excited to apply this kind of framework to it. We’ve already started to build our basis of evidence from both the in
vitro and in vivo sides, she said.
Hartung noted that ToxCast is not a great case study for applying EBT because it has already been subjected to so much
quality control. The important thing for moving forward is the
commitment to be systematic, objective, and transparent, he
said. We desperately need to be objective and discuss biases,
he said.
Many of the tools developed for EBM will fit quite well with
what toxicologists do, Hartung continued. Systematic reviews
can be applied; data appraisals are now under development;
meta-analyses haven’t yet been done, but they’re coming; and
test assessment methodologies can help improve toxicology, he
said.
Scherer pointed out that the area of research synthesis is
quite a new field. Systematic reviews weren’t around before the
1980s, she said. What you are struggling with is a method for
research synthesis in your field. No one has done this before –
that is why it is so difficult.
A part of Cochrane that many people do not know about is
the existence of methods groups, Scherer said. They do studies
on how to carry out the elements of a systematic review. For
example, an information retrieval group goes through and develops search strategies. They figure out the best way to search
for a particular kind of study. There is also a bias methods group
looking for potential biases. Another group focuses on diagnostic test accuracy, and one focuses on statistics. “This is an exciting time for toxicology because you’re right on the edge of
developing these methods,” Scherer said.
Any kind of question can be addressed using an evidencebased approach, she reiterated. The question is critical. It is the
foundation for how you conduct your search and how you appraise the studies that are going to be included in your review.
Mike Holsapple of Battelle, who is also a member of the US
EBTC Steering Committee, pointed out that the draft EBT mission statement suggests that people will use the EBT method
both to sort through the available data and to judge it to facilitate robust decision making, which is at odds with the Cochrane
approach. James Freeman, who chaired this workshop session
and is a member of the US EBTC Steering Committee, pointed
out that, historically, toxicologists did everything from inventing the tests to running them and creating risk assessments.
Toxicologists are used to evaluating their own work, he said.
Silbergeld noted that some kind of division of labor is likely to
be useful, and it seems to have served the Cochrane Collaboration. Hartung said that once the evidence (or the absence of
evidence) has been mapped it can be used for a variety of pur-

poses, and different entities may interpret it in different ways
depending upon their needs.
Martin Stephens of Johns Hopkins University, who is a member of the US EBTC Steering Committee, ended the session by
showing a slide that was originally prepared for EBM by Scherer, and which he is translating to EBT. It gives an overview of
the processes of generating evidence, as well as gathering and
assessing published studies. Different people are involved with
each step; industry, government, and academic labs generate the
evidence; the data generators themselves can gather or assess it,
as can members of the EBTC or others. Others can take it and
integrate it into policy (if appropriate), including whomever in
industry or government makes decisions. In the end, you have
the application to public health.
Once an EBT assessment has been completed, it can also
feedback and inform how new data gets generated and the types
of studies that are conducted, Stephens said. In that way EBT
can help not only to condense existing data but help shape future
studies, he concluded.
5 Workshop Session 3:
Potential Priorities for the Evidence-based
Toxicology Collaboration

This session featured a presentation by Suzanne Fitzpatrick
(see Section 5.1).
5.1 Twenty-first Century Validation Strategies –
Can Evidence-Based Toxicology Play a Role? 9

The National Research Council report, “Toxicity Testing In
the 21st Century: A Vision And A Strategy” (NRC, 2007), described a new vision and strategy for toxicity testing that would
be based on human biology rather than animal biology and
would be less expensive and time consuming. This vision also
involves a strong commitment to the 3Rs – replacement, reduction, and refinement of animal use in experiments. Being
responsive to this progressive scientific perspective would necessitate moving forward to develop, validate, and incorporate
alternative toxicological test methods into the federal regulatory framework.
As stated in the NRC report, “[c]hange often involves a pivotal event that builds on previous history and opens the door to a
new era.” The publication of the NRC report itself was the “tipping point” for a change in toxicology, but validation of these
new methods for regulatory use will be the critical component
in ensuring the vision’s success. Toxicologists have the unique
opportunity to meet these challenges by looking at new approaches, new collaborations, and new ways to take advantage
of 21st century technologies.
Current formal approaches to validation involve lengthy and
expensive processes that require validating in vitro data from a
single assay against in vivo data. These approaches are not relevant or even feasible for the new pathways and endpoints being
measured with high-throughput and high content methods.

9 This section is based on a paper prepared for the proceedings by Suzanne Fitzpatrick and Abigail Jacobs.
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Consequently, applying a “one size fits all” approach to validation is not conducive to the rapid incorporation of emerging science or technology into the regulatory decision-making
framework. As new safety testing evolves, new approaches to
demonstrating that a test is reliable and relevant for a particular
purpose must also evolve.
An example of a new validation strategy is the FDA Drug
Development Tool (DDT) Qualification Process (see Section
4.1). Qualification is a regulatory conclusion that, within the
stated context of use, the results of an assessment with a DDT
can be relied upon to have a specific interpretation and application in product development and regulatory decision making.
Once a DDT is qualified for a specific context of use, industry
can use the tool for the qualified purpose during product development, and FDA reviewers can be confident in applying the
DDT without the underlying supporting data. The FDA DDT
Qualification Program involves a “fit-for-purpose” qualification. It is an objective, science-based approach for evaluating
the relevance, quality, and reliability of a biomarker based upon
its intended use, for example, a test method used as part of a
screening program or a definitive surrogate endpoint in a pivotal clinical trial. Details about the FDA’s qualification program
are available online.10
There is a pressing need to develop and use a structured
evaluative process for new toxicology tools similar to the DDT
biomarker qualification process. This process would consist of
uniform, objective, science-based criteria for systematically determining data relevance, quality, and reliability. Once novel,
cutting-edge methods have been evaluated and incorporated in
the toxicological toolbox, data on a chemical’s effects from new
and existing methods from all relevant studies should be comprehensively reviewed, given appropriate weight, and integrated
in a transparent manner. The resulting document would describe
a robust, biologically plausible understanding of the mode of
action of a chemical and the potential hazards and risks that exposure to the substance could pose to humans and to wildlife.
Regulators must ensure that their toxicological toolbox keeps
pace with advances in science and technology. But regulators
also must determine how much evidence is sufficient to judge
that a new tool is qualified to inform safety decisions that potentially affect millions of consumers. There is a delicate balance
between ensuring safety and avoiding restrictions on valuable
products; this is a continual, unique, and demanding challenge
for regulatory agencies. Any advances in validation must recognize these competing demands that regulators face.
It is now clear that in vivo animal studies cannot be the gold
standard that we qualify new toxicology methods against. Regulators must determine the relevance of in vitro results to what
occurs in humans rather than the concordance of that data to
what occurs in rodents and other test animals.
A key aim of the EBTC is to advance 21st century toxicology
by translating the principles and approaches of Evidence-based
Medicine (EBM) to the evaluation of emerging toxicological
testing methods. Structured reviews of existing evidence are a
key feature of EBM, and translating this to toxicology could

give regulators the needed evaluative procedures to judge the
quality of new toxicological tools through the use of EBT’s systematic reviews and meta-analyses.
Systematic reviews carried out in a regulatory context must
have the ability to look at proprietary data in a transparent manner, while keeping the data confidential and addressing the open
literature as well. Often regulators are criticized for not using
data from the published literature. Applying systematic and
meta-analysis approaches to the published studies in journals
could assist regulators in incorporating these data into regulatory decisions.
There have been some objections to using EBT on the grounds
that toxicologists already use evidence in assessing causation
and reaching regulatory decisions. However, toxicologists
should not let semantics turn them off to this approach. Systematic reviews would offer a complete and rule-based analysis of
data with conclusions that are transparent enough to be reproducible.
What can the EBTC do to begin promoting the use of evidence-based reviews of in vitro toxicology test methods for
making safety decisions for human exposure? A prerequisite
is to develop a strong coalition of scientists from government,
academics, and industry who are committed to working together
to facilitate change. Agreement on a shared vision and a governance plan will give the EBTC a strong foundation to build
consensus.
Single tests alone, even if highly sensitive or specific, can no
longer provide an appropriate assessment of a chemical’s toxicological properties. Toxicologists will need to incorporate information from many diverse sources – omics, animals, tissue
culture, engineered organ systems, in silico, etc., into integrated
testing strategies. The EBTC should help to identify the critical
questions that need to be addressed when assessing the safety of
products. These questions undoubtedly will differ between regulatory agencies and even within the same regulatory agency.
The EBTC could then develop draft evidence-based criteria for
integrating data from different sources to assess the relevance
to humans. How much data are needed to give regulators confidence in a new method? The answer will differ depending on
where the method is incorporated into the regulatory paradigm.
The EBTC should identify both short and long term goals
for addressing the issue of validation of new pathway-based
methods. A good starting point might be the drafting of criteria
for the validation of screening methods, where the levels of
false negatives and false positives are not as critical to safety
assessments.
Evidence-based methods can provide more than a kind of
quality assurance for new methods. They also can be used to
synthesize the toxicological data for a risk assessment. Test cases could be developed, comparing the results of evidence-based
assessments with traditional risk assessments to see which gives
the most clarity to assessing a product’s safety.
Workshops to encourage dialogue and consensus need to be
ongoing to gain confidence in the new validation strategies.
Regulators need to clearly articulate the level of performance

10 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/default.htm
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needed to be adequate for the method’s intended use. Draft
guidance with notice and comment for public input can assure
transparency in the new procedures. International collaborations with complementary research programs could help vet
these new strategies worldwide.
Investments in advancing new validation strategies for 21st
century methods can enable regulatory agencies to better protect and promote the health of people in the United States and
throughout the world. Moving towards evidence-based approaches to validation is challenging but essential to catalyzing
change that would allow us to take advantage of revolutions in
science.
5.2 Invited discussant Tim Pastoor

Tim Pastoor of Syngenta anchored his remarks to RISK21, a
multi-stakeholder project that he is co-chairing. Organized
through the International Life Sciences Institute’s Health and
Environmental Sciences Institute (ILSI/HESI), RISK21 is focused on applying the new toxicology and exposure assessment
tools for the 21st century, as defined by the landmark 2007 NRC
report (NRC, 2007), to what he called a “risk context.”
Pastoor expressed his belief that toxicology is at the brink of
a huge change in how practitioners conduct risk assessments.
The new technologies that are available, together with some of
the new thinking and the impetus provided by the NRC report,
are a mandate to change. “We have dug a very deep hole as
toxicologists because everything is about hazard-based assessment,” Pastoor said. He challenged the audience to begin thinking instead about an approach based on zones of safe exposure.
In place of the conventional approach of initially determining what effects a substance causes, RISK21 posits that the first
consideration should be how much someone might be exposed
to, Pastoor said. If human exposure is minimal to none and there
is evidence that the toxicity is very low, one might do toxicity
testing very differently.
Are we ready to move toward an approach that is exposurebased and focused on safety, Pastoor asked rhetorically. He emphasized the importance of using prior knowledge. The RISK21
group is exploring the idea of systematically assessing the body
of prior knowledge using Bayesian network analysis, such as
the probability within a class of toxicity potency.
Pastoor argued that the point estimates and calculations used
to determine acceptable exposure, such as acceptable daily intake (ADI) and reference doses (RfD), suggest that there is a
bright line between safety and lack of safety. The reality is less
clear-cut.
RISK21 also calls for employing targeted in vitro testing,
in conjunction with pharmacokinetic (PK) data, to narrow the
range of expected toxicity, Pastoor said. In other words, you can
use prior knowledge to make an estimate of what your toxicity
values are likely to be, as well as what the exposure is likely
to be. “Why don’t you just do the studies that are necessary to
refine that knowledge?” he asked workshop attendees.
RISK21 counsels using targeted in vivo studies, Pastoor said.
He presented data from the RepDose database showing the distribution of no observable effect levels (NOELs) for 404 chemicals in mmol per kilogram of body weight per day. The toxicity
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for the group varied over eight orders of magnitude, which he
said “is what you’d expect – it happens in nature.” This gives
you a distribution to work with without doing a single toxicity test, he said. With some targeted testing, you have a good
chance of understanding exactly where your chemical might be,
he contended.
Pastoor noted the importance of comparing the exposure that
people have to a chemical to the doses associated with toxicity. For example, if you know that only a relatively high quantity of a given chemical is likely to be toxic, and the quantity to
which someone is likely to be exposed is much lower, you can
feel pretty certain that it is unlikely to cause harm. In a situation
where there is overlap between the dose likely to be toxic and the
quantity to which people are likely to be exposed, you can refine
your exposure assessment by targeted testing. You can also do
the same thing for the hazard, he said. By doing so, you get a
better idea of the gap between exposure and toxicity, he said.
“Let’s get out of the rut,” Pastoor concluded. The issue at
stake is the protection of human health. “When we’re talking
about priorities, we’re really thinking about how we use prior
knowledge to understand things so we don’t have to kill additional animals in a pointless effort to try to refine information
that we really don’t need.”
5.3 Invited discussant Olga Naidenko

The comments of Olga Naidenko from the Environmental
Working Group reflected a societal view of chemicals management and environmental stewardship.
“Despite the best work that toxicologists have been doing up
until now…. we are still stuck with what many people feel are
… annoying and perhaps even intractable problems,” she lamented. The process for screening endocrine disrupters is not
very effective, occupational chemical exposure in the U.S. is
not adequately assessed, and the best science is not being used,
she argued.
Naidenko said that she agreed with a key point that Fitzpatrick
made in her white paper: “The ability of researchers to develop
and deploy biological profiling and high-throughput/high content methods has outpaced the ability of regulatory agencies to
apply traditional method validation approaches for demonstrating relevance.” In fact, Naidenko said she felt that “the ability of researchers to develop and deploy new chemicals has far
outpaced the current ability of society to assure the safety of
these chemicals for the long-term sustainability of the planetary
society….”
Naidenko also agreed with Fitzpatrick about the need to build
a broad-based coalition of scientists who are willing to work
together to facilitate change and encourage the use of EBT, as
well as on the need to develop uniform, objective, science-based
criteria for systematically determining the relevance, quality
and reliability of new test methods.
Naidenko made some suggestions about obstacles she perceived to EBT’s implementation and how to overcome them.
Anyone who has ever participated in a political coalition knows
that actions of coalitions are strongly dependent on positions of
their participants, which are in turn shaped by their experiences
and values, she said.
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The solution to these pitfalls is transparency about values and
goals, Naidenko said. Open discourse about values ensures that
regulators and stakeholders cannot hide behind “science made
me do it” statements, she said.
Naidenko raised concerns about the white paper’s statement
that, as new safety testing evolves scientists will develop “uniform, objective science-based criteria.” She pointed out that
values and the perception of what is “safe” and what constitutes
an “unacceptable risk” vary within society, between societies,
and between different economic groups, such as workers, consumers, parents, the affluent, and those who are economically
challenged.
Naidenko asked participants to consider “the balance of our
goals in the economics/ecology continuum.” How do we handle
risk-risk tradeoffs, she asked. For example, certain degrees of
public health protection may entail the loss of jobs. This begs
the question of what we can afford.
“We of course believe that our science is objective, but science
is very much embedded in the society that produces the knowledge,” Naidenko said. Understanding the nature of knowledge
is essential for helping us avoid errors in thinking, she said. In
addition to providing useful insights into the issues facing toxicologists interested in using 21st century tools, the study of the
sociology of science and progress may help us save time and
money, Naidenko suggested.
Naidenko commented that what toxicologists are trying to do
via EBT is inherently more difficult than what medical science
has achieved through the Cochrane Collaboration. While Cochrane is focused on a better way to do good by curing patients,
the toxicology collaboration may be seeking to determine the
scientifically, ecologically, and economically acceptable level
of harm, she observed.
We cannot do EBT successfully unless society jointly, transparently decides on its values along the economic-ecological
continuum, she contended. She said she agrees with Fitzpatrick
and Pastoor that we do want to use prior knowledge. We do
want to study the literature on previous stumbling blocks, such
as BPA, to determine what went wrong and what we can learn
from those experiences. We don’t want to spend millions of dollars to end up with something that no one is satisfied with, she
concluded.
5.4 Invited discussant Michael Holsapple

The third invited discussant, Michael Holsapple of Battelle and
a member of the US EBTC Steering Committee, agreed with
the points that Fitzpatrick raised in her white paper and said he
would be presenting some of the issues that the EBTC will need
to tackle in the future.
He emphasized that toxicologists have many topics of interest, but few have the potential for having a greater impact on the
science of toxicology than the challenge of using 21st century
tools, or Tox21c. He said he feels that if toxicologists do not
embrace Tox21c and try to move it forward, the discipline is in
danger of become increasingly marginalized.
The current “menu-driven” approach to toxicology provides
too much information about items of low interest and insuffi-
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cient data on high priority effects, Holsapple said. To amplify
this point, Holsapple quoted from a recent editorial in Science
by FDA Commissioner Margaret Hamburg (Hamburg, 2011),
who was essentially suggesting that toxicology is somewhat
stuck in the past, and we need to be moving forward. The FDA’s
strategic plan calls for improving predictive models and modernizing toxicology to improve product safety, he continued.
Holsapple said that he was struck by how many people on the
US EBTC Steering Committee observed that their understanding of EBT was enhanced by the talks at the workshop. There
is still a real lack of consensus by the Steering Committee on
what EBT is and should be accomplishing, he observed. “We’re
really struggling with what transparency means, in terms of how
we’re going to move this forward,” Holsapple continued. Like
Fitzpatrick, he felt that listening to Silbergeld and Scherer describe evidence-based science had greatly enhanced his understanding of the discipline.
Holsapple said that he felt that members of the Steering Committee would benefit a great deal from an “EBT 101” type of
introduction to the issue. This would help ensure that the ambassadors trying to advance EBT are all on the same page and
articulating the same message, he said.
He said that he is also still struggling with the mission statement. He said his current understanding of evidence-based approaches is that the process involves amassing all of the evidence
on a narrowly defined subject and going through it very systematically, using a priori defined criteria. The analysis involves
making sure the evidence is packaged in such a way as to clearly
show that it presents the best “look and feel” for what the evidence can present right now. “The important thing is that those
involved in the evidence-based approach don’t make the value
judgment; they don’t say ‘yes’ or ‘no’ or it’s ‘blue’ or ‘green.’
The evidence is handed off to someone else,” he summarized.
Holsapple believes the EBTC needs to develop a communication strategy to focus on ensuring that this evidence-based approach is understood. We have to become the ambassadors to
champion that, he said. A key target audience is the public. “If
we don’t bring the public along, they’re going to be blindsided,
and they’re not going to be happy,” Holsapple said. He feels
that the EBTC needs to engage in the same kind of outreach to
other stakeholders because they are going to be very important
to realizing the coalition’s goals.
5.5 Open discussion

Ellen Silbergeld complimented the panel of speakers for moving the group to think about the directions, actions, and opportunities for productive collaborations. She agreed with Holsapple that bringing along “the broader community and persons of
interest will be absolutely critical.”
A wide-ranging discussion of issues related to exposure, dose,
and safety ensued, mostly in response to Tim Pastoor’s invited
commentary. Session chair Rodger Curren, a US EBTC Steering Committee member, asked participants to try to focus on the
issues that the EBTC should be looking at in terms of validation
and understanding how EBT methodology can be supplied.
Richard Becker pointed out that workshop participants seem
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to have different visions for EBT. If we think very broadly, there
are probably different applications of evidence-based approaches that we should be thinking about. We probably also should be
thinking about moving forward within some kind of consortium
to address these, he said. One component of EBT that is top
of mind is 21st century tools and validation strategies for these
tools, per Fitzpatrick’s presentation. That may be one area the
EBTC should consider focusing on, he said.
Becker said that he thought the group needed to look carefully
at the decision paradigm for which those tools are being developed and for which they are intended to be applied. That has to
be integral to the way that we evaluate the data to establish the
scientific confidence in that tool, he said. He noted that Fitzpatrick said the FDA looks for the purpose for each methodology within a regulatory decision-making framework. Similarly,
Becker observed that Pastoor talked about an integrated Bayesian assessment approach that involves looking at knowledge
and targeted evaluation using different methods to provide the
information needed to make the decisions.
Becker posited that the new technologies cannot be evaluated
by divorcing them from the application for which they would
be used. He therefore suggested that it is important to bring forward the tools, together with the data and the context and the
decision framework within which they would be utilized.
Holsapple said that he felt of two minds about his response
to Becker’s comments. “I agree that we need to understand the
context,” he said. “I think that’s essential.” He said that he did
not think it made sense to try to evaluate fitness for purpose for
each of the many assays now available. Instead, he he thought it
made sense to get a fit for purpose for a series of assays.
On the other hand, he pointed out that, as he understood the
evidence-based approach, it is a tool that can be applied to any
question. You define the question up front and define the criteria
a priori to answer any of these questions. This potentially broad
scope notwithstanding, Holsapple argued for the EBTC to go
on record as being involved in validation as one of its major
activities. The other alternative is the more general goal of promoting the beauty of trying to conduct meta-analyses and very
systematic reviews and bring evidence-based approaches into
toxicology, he said.
These are two different paths, although they are not necessarily mutually exclusive, Holsapple said.
Fitzpatrick asked if EBT could be used to frame the question
to see if evidence-based approaches could be used to evaluate
fit for purpose. As an example, she said: “is this method, in this
regulatory context, able to give us assurance that the answer
is what we want?” If the question was framed tightly, it might
result in a lot of EBT evaluations at first, but it would enable
people to evaluate all of the evidence.
Holsapple said that he felt it would work as long as you were
setting a priori criteria to address the question. However, Holsapple said that the answer of whether the fit was good or not
would go beyond what the evidence-based process is designed
to achieve.
Fitzpatrick said her idea was to use evidence-based approaches to analyze the question, and the regulator would look at the
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synopsis to make a decision. “It would be a way to systematically review evidence by the same transparent process,” she said.
Holsapple responded that one thing that was alluded to on the
previous day was for the EBTC to conduct some sort of case
study. In other words, to use the process to analyze some data
that presents a daunting challenge and then have someone look
at the data and make some sort of a determination as to whether
or not the evidence-based process proved useful.
Silbergeld said that she did not think it made sense to try to
tackle a daunting challenge. Pick something that a crisp question can be formulated to address, she urged. Ideally, this subject
should be one that has been the focus of as many papers as possible so there is a lot of evidence to bring to bear. The topic also
should be one for which researchers hope that it is possible to
get somewhere by sifting through the evidence systematically.
Silbergeld again raised the analogy of a courtroom. “It’s not
like a grab-bag of different charges and different laws. It’s a specific case for which evidence has been deemed to be admissible
or not,” she said. “If the charge were different, then maybe different evidence would be admissible.” Formulating the question
crisply is the key to success, she said.
Holsapple responded that, to him, picking a subject that was
data-rich was part of what constituted a daunting challenge.
“What’s necessary for EBT to get some kind of momentum is to
demonstrate that we as a community can apply it and get some
meaningful information from it.”
Fitzpatrick said that in drug development and qualification
there is a “pre-EBT phase.” We come in for a consultation before all of the evidence has been generated to determine what
kind of evidence is needed to give the regulators confidence,
she said.
Thomas Hartung pointed out that what the group collectively
learned yesterday was that evidence-based approaches are a way
of handling information and condensing it. The process is so
good that scientists can rely on the end product without going
through all of the supporting information in detail. The process
ensures that the evidence has been evaluated in a credible process. By this we can help a lot of applied toxicology, he said.
Today we have heard some compelling calls for using the evidence-based process for evaluating candidate drugs and pesticides, Hartung added. It is clear that evidence-based approaches
have the ability to condense information and ensure quality on
all levels. What the presentations and discussions to date have
shown is that one of the priorities for the EBTC is to sharpen the
group’s understanding of what the tools do and do not deliver,
he said.
Hartung said that he was encouraged to hear that Fitzpatrick
had already had positive experiences with applying some EBTlike processes to BPA. “It’s most important that we now build
from these types of cases,” he said. He said that EBTC has some
mechanisms to fund some meta-analyses and studies.
Hartung agreed with Holsapple’s statement about the need to
produce a document that clearly explains what EBT does so that
people are discouraged from using the label for whatever they
think is cool in toxicology at the moment. Holsapple said that,
in addition to defining what EBT is, any document produced
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should also make clear what it is not. Perhaps a flow chart could
be used to show this, he said.
Hartung said that Naidenko’s comments also made clear that,
in addition to aiding the toxicological community, EBT may
help with outreach to other stakeholder groups and the public.
High quality, condensed information could appeal to many others and could be used to inform many processes, he said.
Sebastian Hoffmann of seh consulting, and a member of the
European HTPC Steering Committee, said that from the European perspective, it should be a priority for EBT to be used
not only to assess individual tests but also to develop testing
strategies. He acknowledged that EU and U.S. priorities may
differ.
Naidenko said that it may be important for the group to consider how to get stakeholder buy-in as early in the process as
possible. She also observed that doing case studies and publishing them early on would be a foundation for moving forward.
Gillian Griffin of the Canadian Council on Animal Care
pointed out that the 8th World Congress on Alternatives and
Animal Use in the Life Sciences, held in Montreal last summer,
resulted in a declaration on synthesis of evidence. She noted
that conferees balked at calling it a declaration on systematic
review, in part because people in the audience were concerned
that we really did not have enough in the literature that would
enable us to be able to do a systematic review. Because this is
an iterative process, as we go forward, the information published in the literature becomes richer and we are able to apply it to do better systematic reviews. She said she was very
excited that EBT also is moving in that direction and noted that
a number of other fields are also doing so. Finally, she said she
also felt that public engagement was key.
Doug Keller of Sanofi said that, as the EBTC defines itself
and starts to tackle case studies, it’s essential to establish itself
as an unbiased organization. You don’t want to be perceived as
a group with an agenda to justify pathway-based methods or to
replace animal use, even if that’s the eventual goal that many
people have. The Steering Committee’s composition is helpful
in that regard, but Keller stressed that the group’s credibility
will be established by how it proceeds.
Hartung said that an important aspect of evidence-based approaches is that they provide many tools to help practitioners
avoid bias and to ensure that it does not affect the quality of the
end product. This is, in part, because the process does not allow
for manipulation, he said. Where manipulation cannot be excluded, the process makes its presence as evident as possible.
Silbergeld noted there are two kinds of bias. The first she defined as the National Academies kind of sociological bias, which
is based on where you stand from and where you sit. There is
also bias that is related to how studies are conducted and how
data are collected. That is to some extent independent of the first
type of bias, she said.
The whole reason for initially establishing a priori consensus-based definitions is to avoid bias, Silbergeld continued.
Defining the characteristics or aspects of a paper that increase
our confidence when present and decrease our confidence when

absent allows reviewers to have a common set of transparent
reference points, she said.
Rob Wasserman of EPA’s IRIS program said that his program
is in the process of developing criteria for what constitutes acceptable evidence. He said that, to him, it seems that the first
thing for the EBTC to do would be a comparison involving criteria that already exist, rather than a case study.
6 Workshop Session 4:
Governance and work processes for the Evidencebased Toxicology Collaboration

This session featured a presentation by John Fowle.
The following section (6.1) is a summary of that presentation.
6.1 Governance and Work Processes of the
Evidence-Based Toxicology Collaboration

John Fowle, who recently retired from the EPA, discussed
key points to consider as options for establishing governance
and work processes for the EBTC in a white paper. The options
are modeled after the governance and work processes of the
Cochrane Collaboration and its approach to EBM. 11
The goals of the EBTC include fostering the development of a
process for quality assurance of new and traditional tests for the
assessment of safety in humans and the environment, as well as
providing guidance on evaluating evidence from new and existing tests when assessing chemical safety. The key methods used
by the Cochrane Collaboration include systematic reviews of
relevant literature, such as inclusion/exclusion criteria for published studies and meta-analysis of data. These approaches can
be applied to the EBTC, and in addition, the Cochrane Collaboration approach to governance offers a model for shaping the
nascent organization’s operations and policies.
The EBTC, in order to be successful, will need to reach the
hearts as well as the minds of many individuals in many different areas of expertise to secure stakeholders’ time and effort to
systematically identify and review the toxicology literature. The
organization also will need people to serve on teams to write
reports of the findings; to work to capture the reports in databases and electronic libraries; to help train others; to hold periodic
meetings; and to contribute to all the many other tasks that will
be required if the organization is to achieve its vision. This means
that “buy-in” is needed and that simply copying the Cochrane
Collaboration approach to governance and work processes and
applying it wholesale to the EBTC likely will not work.
Kotter (1996) identifies eight steps to leading change. These
include establishing a sense of urgency, creating a guiding coalition, developing a change vision, and empowering broad-based
action. Kotter also extolls the value of generating short-term
wins at the outset of the process.
Fowle consulted a number of sources of information on the
establishment of governance, policy, and procedures for a nonprofit organization such as the EBTC. “The Basics of Forming a
Nonprofit” checklist from “Nonprofit Law and Governance for

11 http://www.cochrane.org/
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Dummies” (Welytok, 2007) encapsulates advice from various
publications:
To ensure the success of your nonprofit organization, you need
to start with a solid foundation. Take a look at the following
fundamentals checklist so your nonprofit is set up properly
and legal issues are covered right from the beginning.
– Clearly define your mission and its scope
– Put together a business plan and system
– Adopt a set of bylaws
– Recruit a board
– Hold an organizational meeting and define duties and responsibilities
– File for tax-exempt status with the IRS 12
– Register with your state
– Get staff and volunteers in place
It is of critical importance to clearly define the mission and
scope of any organization. Beginning with the end in mind
(Covey, 1989) allows one to visualize what success will look
like in the future by providing a “compass” to help direct the
actions toward the ultimate goal. Thus, the EBTC’s mission and
vision are key elements to consider when establishing procedures for governance and work processes. They define what job
the organization is to do and what a successful future would
look like. All that the EBTC does will derive from and/or be
evaluated against its mission statement.
In addition to the purpose and nature of the organization, a
mission statement has implications for what the organization
will do and how it will do it. A “to do” list can be developed
from a properly crafted mission statement to guide the operations and governance of an organization.
Although the EBTC has not yet adopted a mission statement, it
does have an early draft of one, which is admittedly overly long:
The EBTC will facilitate the systematic, objective, and transparent assessment of test methods to foster the increasing use
of in vitro test data in making safety decisions for human exposure. The EBTC will facilitate the adaptation/development
and use of systematic reviews of methods to identify the most
promising existing/emerging methods so that these may be
used more broadly to generate critical safety data, [as well as]
tools for data appraisal, meta-analyses, and test assessment
methodologies, to identify the most promising existing/emerging methods so that these may be used more broadly to generate critical safety data. The EBTC also will apply these tools
and approaches to the construction of testing strategies to ensure effective and efficient testing, as well as to the synthesis of
data across studies to facilitate robust decision making.
This draft mission statement implies that the EBTC wants to
add value to 21st century toxicology, as well as to traditional
toxicology, by speeding the adoption of the best methods for
next-generation safety assessment testing. It hopes to do this
by adopting the tools and approaches of EBM as used by the
Cochrane Collaboration. A primary activity implied by the
draft statement is to sort out the difficult issues associated with

reviewing data on chemical toxicity from multiple types of
methods and integrating these data to inform decisions about
chemical safety. In other words, how do you integrate data from
animals, tissue culture, high-throughput tests, various “omic”
technologies, in silico approaches, etc. when the results do not
all point in the same direction? A final task implied by the draft
mission statement is to apply evidence-based thinking to the
various existing and new toxicity testing approaches, perhaps
through an adverse outcome pathway approach, to build an efficient integrated testing strategy or to critique a proposed strategy in an unbiased fashion.
A well thought-out and carefully crafted vision statement
is just as important as a mission statement to an organization. While a mission statement speaks to the “head,” a vision
statement speaks to the “heart” by providing the members of
the organization with a picture of how things could be in the
future and how that is of value to them as individuals. The vision is a stretch goal to strive for. Effective vision statements
are easily grasped by all, but are very difficult if not impossible to reach, because they are designed to stimulate continual
improvement as well as to provide a sense of purpose and a
common goal.
To aid the EBTC leadership as they develop a vision for the
organization, Fowle posed the following questions, derived
from the Cochrane Collaboration’s retrospective analysis 13:
– What is the organization (what are our aspirations for it)?
– Who does it serve (who are our customers)?
– Who wants what, when, how (what are the needs and expectations of our stakeholders)?
– What will the organization provide (what are our products
and services and what are the needs of third party users who
will leverage our products and services into their own)?
– How are we differentiated from others?
– What is in scope?
– What is out of scope?
A similar set of questions also could help the organization fine
tune its mission statement, he pointed out.
Fowle also talked about the value of having a solid business
plan and pointed workshop attendees to sources for advice on
writing a business plan for a nonprofit corporation14.
Fowle acknowledged that properly developing and adopting
a set of bylaws may seem too tedious and time consuming for
many, given the enthusiasm to get on with advancing a new organization’s mission. However, in the spirit of “going slow to go
fast,” he argues that it seems worthwhile to take whatever time
is needed to place the organization on a firm footing to avoid
misunderstandings, wasted time, and potential hard feelings in
the future. He pointed out that “Robert’s Rules” comprehensively classifies organizational rules based on their application
and use and on how difficult they are to change or suspend (Jennings, 2006). He recommended that the EBTC consider adopting Robert’s Rules of order, amending them as needed to meet
the organization’s needs.

12 Internal Revenue Service of the US federal government.

13 http://ccreview.wikispaces.com/file/view/Collaboration+review+-+Recommendations+Report+-+FINAL+2009.pdf
14 http://smallbusiness.chron.com/write-business-plan-nonprofit-corporation-3061.html
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The EBTC also will need to file for tax-exempt status with the
IRS and register with the state, and Fowle presented sources for
doing these things, as well as for hiring staff.15, 16, 17
The Cochrane Collaboration’s work processes and governance are described in the “Newcomer’s Guide” on the Cochrane
Collaboration website.18 Further details about governance and
work processes can be found in The Cochrane Manual.19 Cochrane entities receive their funding from different sources but
agree to follow the policies and practices of the Cochrane Collaboration.
The Cochrane Collaboration also employs two ombudsmen
to help resolve areas of conflict that arise between people or
entities, for which the usual process of involving their Centre
Director has not been sufficient.
The Cochrane Collaboration’s central functions are funded
by royalties from its publishers, John Wiley and Sons Limited,
which come from sales of subscriptions to the Cochrane Library
containing the publications produced by the Cochrane Collaboration. The individual entities of the Cochrane Collaboration are
funded by a large variety of governmental, institutional, and private funding sources and are bound by organization-wide policy
limiting uses of funds from corporate sponsors. The Cochrane
Collaboration’s sources of support can be found online.20
Fowle offered his thoughts on how well the Cochrane Collaboration model meets the EBTC’s needs. While the EBTC
has methodological and informational components like the Cochrane Collaboration efforts, the audiences of the two entities
are likely to be different in a few important aspects. The medical
orientation of the Cochrane Collaboration is likely more accessible to individuals than is toxicity test qualification, which is a
central focus of the EBTC, given that individuals are directly
engaged in health care issues but are not directly engaged in
the types of decision making that occurs in industry and regulatory agencies. Additionally, the various health outcomes that
the Cochrane Collaboration deals with are real and can be seen
in patients by physicians daily, while toxicity outcomes in human populations are sometimes theoretical because of measures
taken to avoid any adverse outcomes. Finally, the Cochrane
Collaboration deals with human health issues only.
Because toxicology deals with environmental health as well
as human health, Fowle suggested that the EBTC may wish to
adopt this two-prong focus so that it is able to address the environmental health mandates of US agencies such as EPA, the National Marine Fisheries Service, the National Wildlife Service,
the United States Geological Service, and corresponding state
entities that are responsible for assessing risks to wildlife and
ecological systems.
Fowle raised points to consider for a future discussion about
the formation, governance, and work processes of the EBTC.
The EBTC’s success will depend in large part on the enthusiasm
and engagement of many people of different backgrounds and
15
16
17
18
19
20

92

in different locations to do the work of the organization. He suggested that it would be possible to use questions employed by
the Cochrane Collaboration’s retrospective analysis (see Section 6.2) to elicit input from the interested stakeholders about
what the EBTC should be, what it should look like, and what it
should do to maximize the chance of success.
Finally, Fowle offered two proposals aimed at triggering discussion and identifying action items and next steps:
1. Establish the EBTC as a nonprofit organization following the
general approach outlined in this white paper.
2. Base the EBTC Governance and Work Processes on the specific model of the Cochrane Collaboration, including its principles, with modifications as appropriate to suit the EBTC
needs.
6.2 Invited discussant Roberta Scherer

In response to the points John Fowle raised about the steps
needed to create an organization and procedures for the EBTC,
Roberta Scherer of the Cochrane Collaboration and Johns Hopkins University described how the Cochrane Collaboration has
addressed these issues over the years.
She began by describing the evidence-based health care process. Cochrane becomes involved after evidence on a particular
medical topic – often in the form of a clinical trial – is generated. This evidence may or not have been published. Cochrane
conducts a systematic review bringing the evidence together,
synthesizing it, and doing a meta-analysis on it. This evidence
is then used by professional societies or others to make decisions. It also may lead to policy that is applied in the healthcare
setting.
Scherer underscored that the evidence is only one aspect of
the situation. The other aspects – what are used to apply the
evidence – are clinician expertise and patient values.
Scherer noted that the collaboration’s name honors Sir Archie
Cochrane, a British epidemiologist. In 1979, he criticized his
profession for failing to “organize a critical summary by specialty or subspecialty adapted periodically of all relevant randomized control trials.” In the 1980s, Sir Ian Chalmers, an obstetrician, took up Cochrane’s challenge and organized a group
of people to develop the Oxford database of perinatal trials. The
group gathered all of the randomized trials having to do with
perinatal care.
In 1992, the British National Health Service funded the first
Cochrane Center. The Oxford database of perinatal trials that
Chalmers amassed in the 1980s served as a proof of concept
study and precipitated the idea that systematic reviews of randomized controlled trials testing various medical interventions
could be done for all of medicine. The purpose of the original
center was to facilitate the preparation of these systematic reviews. The Cochrane Collaboration as such (not just a center at
Oxford) was launched in 1993.

http://www.sos.state.md.us/charity/non-profit.aspx
http://www.sos.state.md.us/charity/checklistnonprofit.pdf
http://www.answers.com/topic/nonprofit-organizations-and-human-resources-management
http://www.cochrane.org/about-us/newcomers-guide
http://www.cochrane.org/policy-manual/welcome
http://www.cochrane.org/about-us/funding-support
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The Cochrane Collaboration presents summary data in the
form of “forest plots” to graphically depict the trials used in
evaluating evidence on a particular topic and the level of concordance between the trials, Scherer told attendees. The plot includes a horizontal line for each trial evaluated; the line’s length
is based on its 95% confidence limits for the piece of evidence
in question. A vertical line indicates the area of no difference,
and a small diamond denotes the pooled result of the meta-analysis. The width of the diamond represents the confidence in the
result, in terms of the meta-analysis.
The Cochrane Collaboration’s “product” is The Cochrane Library, which Scherer said is widely considered to be the single
best source for reliable information on the effects of healthcare.
The Cochrane Library includes the Cochrane Database of Systematic Reviews. The database includes more than 4,500 fullprotocol reviews, as well as the published protocols themselves
and methodology reviews.
“We publish our protocols before we do the review; the protocols are also peer-reviewed by experts to make sure that our
reviews will be relevant and important,” she said. The library
includes a register of all of the clinical trials that have been identified via electronic and hand searching.
The methodology reviews are systematic reviews of EBM/
HC research methods. The Cochrane methodology register is a
collection of studies pertaining to research methodology.
Scherer went on to describe a Cochrane review as a review of
existing knowledge that uses explicit and scientific methods. All
reviews are crafted at the outset to include a clear description of
how they are going to be done, and all are designed to follow the
rules the organization has created to ensure that all of the information about the review process is transparent to all observers.
Cochrane reviews include a clear description of the research
question. To avoid duplication of effort, each review is registered before the protocol is written to ensure that the questions
are relevant, important, and have not already been asked by
someone else. Each review specifies the inclusion and exclusion criteria for the randomized control trials that will serve as
evidence. The review stipulates how the reviewers are going
to identify this evidence, including which databases they will
search, and whether any searching will be conducted manually.
Reviewers define the search strategy they will use before they
begin because that will be part of the publication. Reviewers
specify the methods that they will use to assess the risk of bias,
as well as the methods that will be used both to extract and to
summarize the data. Studies are examined closely to see if they
are similar enough to pool study results, i.e., whether there is
clinical heterogeneity. Excessive clinical or statistical heterogeneity would preclude pooling study results.
Scherer averred that the strength of Cochrane reviews is their
rigorous methodology. They are collaborative efforts, and it is
not unusual to have an international group of authors.
Scherer also pointed out that reviews are performed independently of industry funding to avoid the perception of bias.
Scherer then provided details about the Cochrane Collaboration on five points to aid in comparing it to EBT.
1. Mission. The Cochrane Collaboration is international, and it
includes people in both developed and developing countries.
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The collaboration translates Cochrane reviews into other languages.
2. Values. The Cochrane’s values are the foundation for what
the organization does. They explain how the organization
achieves its mission. The organization’s values include collaborating, avoiding duplication, minimizing bias, keeping
up-to-date, ensuring relevance, and ensuring access.
3. Business plan. The Cochrane Collaboration exists for people who need the evidence – healthcare providers, decisionmakers, consumers, and researchers.
4. Funding plan. The initial funding for Cochrane was by
government agencies, especially those in the U.K. The organization became a nonprofit in 1996. Royalties from the
Cochrane library are used for Collaboration-wide endeavors
and to support annual meeting costs. Other than that, each
entity is required to obtain its own funding.
5. Bylaws. Cochrane developed a policy manual that is available online and updated as needed.
The first thing the Cochrane Collaboration did was to hold an
organizational meeting. It included 70 people from nine countries. The organization now has 28,000 people in more than 100
countries, Scherer said.
The Cochrane Collaboration steering group’s first meeting
was in 1994. Scherer said that the steering group focused on incorporating the organization and planning the bylaws, as well as
creating the software and discussing how to create a handbook
to describe how to do the reviews.
Soon after the organization was launched, it developed software for conducting reviews. The organization also developed
ARCHIE, an online repository for directories, reviews, and files
shared by people within the Collaboration – similar to current
cloud computing. The organization also has developed training
materials and sponsors workshops to train people in conducting
systematic reviews.
The Cochrane Library was created very soon after the formation of the organization. It was initially published and made
available online in 1996, and the online Cochrane journal is now
published monthly. More recent activities include the review of
diagnostic tests.
Scherer concluded by exhorting the audience not to forget
about what she called “the heart.” The operation of the Collaboration has not always been a smooth ride. However, because
everyone involved in the Collaboration shares the same vision
– the heart – it has been possible to get through tough times.
She said that while the EBTC needs to come up with bylaws, it
is necessary to be flexible – what the EBTC chooses to do now
may not be relevant in 15 years. Finally, she said that the transparency and methodological rigor based on the empirical studies that underpin the Cochrane reviews are worth emulating.
6.3 Invited discussant Rashid Shaikh

Rashid Shaikh of the Health Effects Institute (HEI) described
a different organizational model for the EBTC, one that has
proven successful in the environmental health and toxicology
space. Rather than a detailed description of how to set up the
organization, he focused on describing what the HEI is, how it
is organized, and what it has achieved.
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He stressed that establishing organizations as independent
and impartial is critical to establishing credibility with both the
stakeholders and the larger public. Independence and impartiality also are intertwined with the other key issues of funding and
governing structure. Shaikh emphasized that communication
with the scientific community, the public, and decision makers,
is also very important.
Shaikh explained that HEI was formed in 1980 in the context
of the Clean Air Act’s section §202(a)(4), which required automakers to test the health effects of automotive emissions. At that
time, the science on which decisions about air quality standards
were based was highly contentious. Industry leaders and EPA
officials were motivated to find a better way to produce science
that all parties would find trustworthy.
According to Shaikh, HEI is structured to maintain credibility and transparency on scientific issues pertinent to regulatory
questions in the air pollution and health areas, which are often
controversial. The organization strives to maintain a balance of
government and industry funding. While the EPA and the motor
vehicle industry provide a significant portion of HEI support, other government and private groups also support the organization.
HEI has an independent board of directors and two scientific
committees, Shaikh explained. The people serving in these capacities are respected senior leaders, recognized for integrity
and scientific accomplishments, and are not employed by the
auto industry or other government agencies associated with
Clean Air Act regulations. He added that HEI does not take
policy positions and that its work is solely focused on scientific
research and evaluation.
HEI’s mission is to provide independent, impartial, highquality and timely science on the health effects of air pollution.
The outlines of HEI’s work are planned in advance through a
comprehensive process: HEI consults with EPA and automotive
industry sponsors, as well as other agencies, including the National Institute of Environmental Health Sciences (NIEHS), the
Department of Energy (DOE), and the Federal Highway Administration (FHWA). The scientific community and a wide variety
of NGOs and other groups are also invited to offer suggestions.
Through this process, HEI develops a blueprint for five years of
work, which is termed their Strategic Plan.
Once the Plan has been completed and the outlines of the research agenda have been set, the research to implement it begins. HEI develops requests for applications and funds research
through a competitive process. Research is overseen by HEI
staff and the Research Committee. At the end of the research
phase, each investigator prepares a report, which describes the
work in far greater detail than scientific papers. Next, the Review Committee, which has no role in selection or oversight of
the research, conducts a peer-review of the report and prepares
a commentary. HEI publishes the report and commentary on its
website and in print.
From time to time, HEI also prepares broad reviews of a field
of science, for example, health effects of exposure to trafficrelated air pollution or health effects of ultrafine particles.
HEI selects its board of directors after consultation with
HEI’s core sponsors, including the EPA Administrator and a majority of the motor vehicle industry. The scientific committees
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– including the Research and Review Committees and special
review panels – are appointed by the Board; for major appointments, such as chairs of committees, HEI sponsors may also
consulted. The board, scientific committees, and staff all must
undergo a conflict of interest disclosure process annually.
Shaikh emphasized that one of HEI’s key attributes is transparency, which includes full public disclosure of all results, both
positive and negative. HEI reports are detailed and comprehensive, and the accompanying commentary provides both the context and evaluation of the work.
Shaikh stressed that HEI also is committed to allowing access to data and other details to the entire scientific community. Many HEI reports include extensive appendices that have
original data or detailed data summaries. Following publication,
access to data and methods are made available to other investigators.
Other partners have joined HEI over the years, including
other government agencies, the oil industry, and some chemical
companies. Other organizations that support HEI’s work include
the DOE, the FHWA, the American Petroleum Institute, CONCAWE, Hewlett Foundation, the Asian Development Bank, and
others.
6.4 Invited discussant Dennis Devlin

Dennis Devlin, ExxonMobil’s environmental health advisor, is
also a board member and current president of the Health and
Environmental Sciences Institute (HESI), whose mission is to
bring scientists from academia, government, and industry together to address health and environmental issues. He was representing HESI as a discussant.
Devlin complimented Fowle on his white paper, which he
said served to lay down the foundation for furthering EBT. His
goal, he explained, was to discuss practical considerations related to putting together a nonprofit organization and to respond
to the questions that Fowle suggested he address.
Devlin felt that the mission and vision were key statements
for defining an organization, ensuring long-term commitment,
and reaching out to potential funders. He pointed out that a
mission should succinctly describe why the organization exists
and that the vision should describe the organization’s aspirations for what it will achieve. For both a mission and vision,
Devlin stressed the importance of being precise and transparent
so people have no doubt about why the organization exists. In
considering the draft EBTC mission statement, he opined that it
read more like a mixture of a mission statement, a vision, and
work processes. All of these are very important, but each separate statement has a concrete purpose.
Devlin proposed a few mission statements for the EBTC for
attendees to consider, such as “to add value to 21st century toxicology by speeding the adoption of the best methods for nextgeneration safety assessment testing.” Next, Devlin proposed
a vision statement for the organization: “Enhanced decisionmaking for safety assessments based on the development, assessment, and adoption of evidence-based methods and testing
strategies.”
Devlin said that it was important for a science-oriented nonprofit organization to divide its governance and procedural isAltex 30, 1/13
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sues into two camps – administration and the scientific process
of the output – and to consider these issues separately. Nonprofit organizations require a number of administrative tasks to
be completed, including developing a business plan and a board
of directors, which would be a group of experts separate from
the scientific Steering Committee. It would not be appropriate
to put the top-notch scientists on a board of directors dealing
with budgets.
The administrative plan requires external expertise, including
a facilitator, lawyers, finance, communication, and human resources. Devlin felt that the plan proposed by Fowle represented
a good starting point in incorporating Nonprofit Law & Governance For Dummies.
Devlin noted that developing a strategic scientific plan will
take time and a diverse group of dedicated stakeholders, but the
effort is certainly worth it. One of the steps that such a group
would take would be to confirm and adapt the mission and the
vision and use them to develop the strategic plan.
To illustrate how strategic planning can work, Devlin explained how HESI does it. HESI’s scientific plan is always five
years out. To meet that challenge, HESI has four strategic priorities. For each priority, there are supporting objectives. Importantly, there is a background document that clearly articulates
accountability. Devlin showed the group HESI’s strategic plan
for 2011-2015 to illustrate how this kind of information can be
presented concisely and clearly to keep everyone on the same
page.
Devlin remarked that the EBTC’s mission statement should
be crafted in such a way that everything the organization does
and/or could do can be evaluated against it.
In response to the question of “what are the needs and expectations of our stakeholders,” Devlin said that he didn’t know the
funding mechanism and didn’t see relevant details in the documents. He asked whether the funders have special interests. For
an organization like this, having short-term success is important
both to maintain morale and to ensure funding, he said. He advised the EBTC to try for a success, even a small one, within
3-4 years.
Devlin suggested that the organization should provide tools
to assess methods in the “increasingly diverse toxicology toolbox,” as well as reviews identifying the most promising existing
and emerging methods. The EBTC may maintain databases and
an electronic library to provide access to guidance and assessment documents.
An important issue is how the EBTC is differentiated from
other groups and that, in order to do this, one must consider who
the “others” are. Devlin believed this particular endeavor has
many “others” and therefore the EBTC needs to differentiate
itself and then to actively decide if it will collaborate or compete for both experts and dollars. The presumption is that EBTC
will be collaborating, because working together and dividing
the pieces can be a good way to produce useful results.
In terms of structure, Devlin recommended simplifying the
Cochrane Collaboration’s approach, which he thinks has merit.
He observed that review groups that find “evidence” and pre-

pare, maintain, and update reviews may make sense, for example. The question is: Will the EBTC provide the information
for free? (The Cochrane reviews are available via subscription.)
Review groups should likely be formed around certain technical areas, beginning with something that is achievable, perhaps
developmental toxicity.
Devlin said he also felt that methods groups would be useful
to improve methods to capture and use evidence, conduct, and
apply reviews. Some kind of a users’ network would be useful,
he noted.
The board and the scientific steering group, as well as the
funders, will decide what structures/entities should be established. The board also will determine who the leaders are. In
the US, nonprofit organizations require boards of trustees to be
responsible for the oversight of the entire enterprise, including
the chair and vice chair, secretary, and treasurer.
The role of the executive director is critical, Devlin said. That
person must focus on short- and long-term strategies, staffing,
and many other important issues.
The steering committee is going to focus on the technical content. It could be a subcommittee of the board, he pointed out.
Membership for the board and steering committee could begin
with the existing steering committee. Key questions to consider
include whether funders require representation and whether
there is a future role for official members/participants. He said
he doubts whether EBTC needs all positions of the Cochrane
Collaboration. Fit for purpose is what is needed, he said.
Devlin thought that one area where the Cochrane Collaboration may not be a good starting point is in developing the
EBTC’s bylaws, partly because Cochrane is essentially a UKbased organization. It would probably be better to work with a
group more familiar with US law. Devlin concluded by showing
the bylaws for HESI, which he said were quite a bit simpler than
the Cochrane Collaboration’s bylaws.
6.5 Invited discussant Andrew Rowan

The final discussant was Andrew Rowan, who is the CEO of the
nonprofit Humane Society International, as well as a member of
the Human Toxicology Project Consortium, which seeks to accelerate pathway-based approaches to toxicology.21
Rowan welcomed the attention to good management practices, arguing that not nearly enough attention is paid to such
issues in the nonprofit world.
Rowan counseled that the name “evidence-based toxicology”
may be off-putting to some, given that “all of us – I would hope
– are using evidence.”
He questioned the frequent calls for impartial people in endeavors such as the EBTC. “There’s not an individual in this
room who is impartial, in the sense of being completely blank
without opinions, biases, or prejudices,” he contended. “I would
much rather that we have partial people who are identified with
particular positions arguing vigorously on behalf of their positions,” he said.
Part of the impetus for the Cochrane Collaboration was that
peer-review was not doing what it should be doing, Rowan said.

21 http://htpconsortium.wordpress.com/
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Peer-reviewed papers are no doubt preferable to papers that
have not gone through peer-review, but they are not necessarily
great, he said.
In the context of the need to objectively assemble evidence,
Rowan argued that emotion is an important part of decision making. He cited the work of Antonio Damasio, such as Descartes’
Error, in revealing how important emotion is in decision making. Damasio observed that when emotion is eliminated via a
frontal lobotomy, people’s ability to make decisions is impaired.
Lobotomized people cannot distinguish between important and
unimportant decisions, Rowan explained.
“In fact, the human brain is a rather poor mechanism for deciphering large sets of conflicting variables,” Rowan said. We
tend to eliminate a whole lot of stuff because of emotional commitments that have been built up over the years, and then we can
make a decision between two or three options, he observed.
People are also good at intuitive decision making. Efforts to
program computers to be chess masters have revealed how complicated intuitive decisions really are, he said.
Rowan’s plea to the group was not to seek complete impartiality by avoiding corporate funding. “Corporate funding can be
very useful,” he observed. “It can bias results if you let it, but if
you have NGO activists in the system, it probably won’t.” He
agreed with his predecessors on the value of transparency.
Rowan agreed with some researchers who have argued that
most animal research is poorly designed. Much of it is not
double-blind, for example, he said. There are interesting issues
involved in what we accept as evidence and how much we will
accept as evidence, Rowan continued.
Rowan expressed his belief that mission and vision statements should be as concise as possible, as well as memorable.
He then proposed for the EBTC mission statement, “to enhance
trust in and integrity of toxicology and regulatory science” and
for the vision statement: “to create a safer world for humans,
animals, and the environment.” He posited that everyone in the
room could agree that these were worthy goals.
Rowan argued against following the Cochrane Collaboration’s path into becoming a publishing company. “Having to
pay a publishing company for access to these materials, to me,
is not transparent,” he said. “I think transparency requires open
access.”
Funding issues are important, Rowan continued. He urged the
EBTC to be completely transparent regarding where its money
comes from and where it goes. Although he said that this information is available for the Cochrane Collaboration in the U.K.,
he was unable to find funding information for its U.S. arm.
Rowan concluded by reiterating his observations that corporate money might prove helpful to the EBTC and that transparency is likely to serve the organization well.
6.6 Open discussion

Ellen Silbergeld opened the discussion by commenting that a
good next step might be to try out some examples in an effort
to find out how to operationalize the concepts that had been discussed during the workshop. She said that this could build confidence and shape the way that the vision statement is formulated.
There are still a lot more things that need to be thought through
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about how this will actually relate to and improve whatever our
separate visions are of toxicology.
She proposed that the next step might be to put out an open call
for nominations for crisp proposals that might fit into two areas:
1. Applying EBT tools in evaluating a method. For example,
all in vitro tests for estrogenic activity might be evaluated for
evidence of disruption of estrogenic function in humans.
2. Looking through the toxicological literature on dioxin and
see if one can do a systematic review examining the evidence
associating exposures to dioxin with developmental toxicology – or some other endpoint that one could succinctly
phrase.
Silbergeld said that she would be wary of joining an organization aimed at promoting something like EBT without having
a sense that this really is something that our field is ready to
incorporate. She also argued for a broader vision beyond advancing in vitro methods. Think of Cochrane’s vision, which is
to improve healthcare, she pointed out. She therefore suggested
that although one component of the EBTC’s mission could be
to advance new methods, restricting it to that would limit consumer and public interest in and support for this activity.
John Fowle asked Roberta Scherer to say more about the 1993
pilot project that led to the creation of the Cochrane Centers and
how it served as a driver that gave the organization momentum.
Scherer said that the initial development of the Oxford Database
of Perinatal Trials was a proof of concept that showed that evidence-based medicine evaluations were possible. However, she
also noted that a concerted effort to do systematic reviews was
happening at the same time. “It was an intersection of a need
and the methodology being there and developed at the same
time,” she observed. The Oxford Database of Perinatal Trials
showed that this intersection could result in something that was
valuable, she said.
Fowle said that his research drove home the point that it takes
a lot of work to set up an organization and, consequently, it is
necessary to be fully committed to it and have clear objectives
for it. To that end, he said it could make sense to develop a
confidence-building pilot project first. Shaikh agreed, suggesting that a pilot activity could be undertaken while some other
things are being put into place.
Naidenko observed that it is important to consider who the
organization’s users or clients will be. The Cochrane example
seems like it was a lot easier to pull off.
Fowle said that a pilot project could generate an “early win”
and thereby help drive funding and support for EBT. He agreed
with Naidenko that considering who the organization’s clients
would be may also be helpful in this regard.
Terry Quill of the Quill Law Group, who was trained as a
toxicologist, observed that the conference seemed to play out
something like a roller coaster ride. He concluded that EBT for
the 21st century is associated with two issues. The first is evidentiary science and how toxicology should deal with that in the
future with the idea that something different is needed. The second issue is the new 21st century techniques and how the field
is going to deal with them. “I’m afraid that what’s happening is
that, depending on who is talking, there’s an emphasis on one
side or the other.”
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Quill asked the participants if what the group wanted to do
was to use weight of evidence in toxicology in ways it has not
yet been applied. “If that’s what this group wants to do, there’s
certainly a need for it,” he commented.
Quill observed that the new techniques now available to toxicologists have many potential benefits, including saving money
and time, as well as facilitating better health decisions. “On the
other hand, we could spend more money if we have higher false
positive rates,” he said. To him, this raised the question of what
the group was going to do to see that the techniques are properly
validated, relevant, and useful.
Validation is going to be key, Quill continued. “I’m afraid of
the possibility that we may just throw these assays out there and
people will misuse them and misuse the data,” he said. If that
happens, he posits that the field will be in a worse position than
it is now.
Rowan commented that the key difference between in vivobased toxicology and in vitro systems is the volume of data the latter produces. Within a year, we could test all the 30,000 REACH
chemicals for which there is currently very little data and produce
some biological data with 200 different assays at 15 different concentrations. It’d cost about $ 1500/chemical,” he said.
“What the data means is of course another issue,” Rowan
continued. But he argued that the whole-animal assays conventionally used in toxicology studies have never been validated,
beyond the fact that they were being conducted on mammals
and humans are mammals.
According to Rowan, “[w]hat we’re doing currently is not going to get us very far very fast. Even if we have more questions,
we’re not going to do more animal testing because the capacity
isn’t there to do it. The answers also aren’t there from historical
animal testing. Do you think $ 35 million for more BPA studies
is going to produce a clearer outcome for BPA? I don’t. Probably what will happen is the corporations will slowly move away
from it because it’s problematic.”
“It’s the volume of data that’s going to be the real driver of
this, and the fact that we’ll have to interpret it as we go along,”
Rowan summarized.
Richard Woychik of NIEHS felt that Silbergeld’s comments
at the beginning of the open discussion were spot on. “It’s very
important to define what EBT is and what it’s not. I hope that
it’s not just in vitro studies. While at some point way down the
road a series of in vitro studies may be predictive for toxicology,
I don’t think we’re there yet. Nor do I think we’re going to be
there in the near term.”
Finally, Woychik said that he agreed with Silbergeld about the
need for a crisply defined pilot study with some specific objectives.
Thomas Hartung thanked the people who contributed to the
discussion for their thorough analysis and the excellent food for
thought that it provided. “It’s most important that we keep the
ball rolling now, because we are at a critical stage of forming
something that is more than coming together.”
The transparency aspect and financial considerations have
been mentioned several times, he pointed out, and he said that
he wanted to disclose some of the details the he had not previously mentioned.
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We at Johns Hopkins are very much committed to EBT, Hartung stressed. His endowed chair is in the denomination of EBT
because the Doerenkamp-Zbinden Foundation in Switzerland,
which endowed the chair, and Johns Hopkins agreed that this
is a worthwhile effort. This is a continuation of the work that
Hartung began at ECVAM.
That said, Hartung stressed that his institution’s commitment
to EBT does not imply any ownership. “We don’t want to own the
process, but instead to help it along, and we will be very happy if
the process is taken further by others in the future,” he explained.
EBT is not intended to be focused on alternative methods under
a new name, he stated. Nor is it toxicology of the 21st century
under a new name. It is meant to be something that adds a component that is lacking in the field of toxicology, he said. It is a
driving force towards guiding the way we handle information. It
is not meant to produce new methods or to replace methods. It is
meant as a process of bringing a certain type of thinking into our
debates, which might be beneficial for all of us.
Johns Hopkins’ EBT effort has continuing support from the
Doerenkamp-Zbinden Foundation. This will enable it to provide
very limited funding for carrying out workshops and dedicated
small studies via organizations such as the Transatlantic Think
Tank for Toxicology (t4). We are trying to provide compensation to individuals who want to conduct some type of systematic
reviews. At present, the amount available for agreed, dedicated
studies is € 10,000 each, which at the time of the workshop
equated to between $ 13,000 and $ 14,000. Hartung said he
hoped that the funding would help motivate people to initiate
reviews and to compensate them for some of their costs. It will
be linked to the opportunity to publish the review in ALTEX,
which currently has an impact factor of 4.4, he said.
Hartung said he is discussing with his Center’s management
the possibility of providing additional funding for encouraging
the production of systematic reviews in the future. He said he had
between $ 200,000 and $ 250,000 per year to sponsor research,
and some of this might become available for systematic reviews.
Hartung said that a philanthropic donor has provided funding
to establish and maintain the EBTC secretariat; this represents
the most important source of funding via an agreement that is
valid for five years. The funding supports Martin Stephens as
the organization’s director, as well as a support person. It also
includes funds for supporting steering group travel. Taken together, this suggests that the EBTC has some foundation for future achievements. The next steps are to move ahead to discuss
the organization’s structure, as well as potential pilot projects.
He concluded by saying that the day’s discussions had been
very helpful.
7 Discussion
7.1 The nature and scope of evidence-based
approaches

The workshop served to clarify the nature and scope of evidencebased approaches in general and EBT in particular among the
participants. Some participants equated EBT with test methods
validation, rather than as a set of approaches and tools to as97
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sess the evidence on any well-framed question in toxicology,
only inter alia including questions regarding test method performance. By the close of the workshop, participants confirmed
that they better understood evidence-based approaches and the
applicability of EBT. Participants also grasped the distinction
between EBM/EBT’s distillation of the evidence and any policy
decisions that others might draw from the evidence.
This greater understanding of evidence-based approaches was
largely a consequence of the presentations by Ellen Silbergeld
(Silbergeld and Scherer, 2013) and Roberta Scherer (Section
6.2), as well as their comments and Thomas Hartung’s comments during the open discussions. The nature and components
of a systematic review became clear. In addition, the following
points were emphasized:
– Any policy-related decisions informed by systematic reviews
are based not only on the evidence, but also on professional
expertise and – in the case of EBM/HC – patients’ values.
– An organization’s values are an important part of its identity, and the resulting shared vision can carry an organization
through difficult times.
– Taking industry funding for particular reviews could be perceived as a source of bias.
In addition to a general orientation to evidence-based methods in
medicine/health care and toxicology, Ellen Silbergeld mentioned
examples of some of the few systematic reviews that had been
conducted in toxicology, an approach that she and her colleagues
have pioneered. These case studies examined the effects of lead
and arsenic on human health and illustrated the use of forest plots
(Navas-Acien et al., 2006, 2007). These were examples of the application of evidence-based methods to hazard assessment. The
written version of Silbergeld’s presentation, co-authored with
Roberta Scherer (Silbergeld and Scherer, 2013), takes a somewhat more conceptual approach to the subject, providing a practitioners’ view of the nature and importance of evidence-based
approaches in medicine/health care, as well as the potential and
the challenge of translating these approaches to toxicology.
The commentary by Kim Boekelheide – who is by training
a physician familiar with EBM/HC – noted important differences between clinical medicine and toxicology, including the
diverse experimental approaches in toxicology, which would
make evidence synthesis more challenging (Section 4.2). He
raised the important question of the extent to which EBT approaches might be able to prospectively guide new studies in
a field, in addition to providing retrospective analyses of past
studies. Others noted that once an EBT assessment has been
completed, it also can provide feedback and inform how new
data is generated, the types of studies that are conducted, and
how studies are written up for publication. This feedback loop
can help reduce the elements of bias and increase study quality
in the discipline as a whole.
George Woodall of US EPA’s National Center for Environmental Assessment noted that many of the recommendations
made during the workshop are also made in the NRC’s recent
review of the IRIS program’s assessment of formaldehyde
(NRC, 2011). He noted that those considerations are being integrated into the IRIS program, which was encouraging to EBTC
members.
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7.2 General themes and recommendations

Several general themes and recommendations emerged from
the workshop. First, the learning process during the workshop
(see Section 7.1) led many participants to suggest a primary role
for the EBTC in education and outreach on evidence-based approaches.
A second over-arching theme was an obvious need to demonstrate the value of evidence-based approaches to toxicology
through case studies. Two of the three presentations featured as
“case studies” in workshop Session 2 (Daland Juberg’s and Patricia Harlow’s – see Keller et al., (2012) and Section 4.1, respectively) have clear relevance to future work applying evidencebased approaches to 21st century methods, but given the current
embryonic state of EBT, these presentations were necessarily not
demonstrations of how EBT had already been applied. However,
Silbergeld’s presentation in Session 2 (Silbergeld and Scherer,
2013) did summarize some evidence-based studies of the literature associating specific chemicals with certain adverse effects.
Nonetheless, it was clear that the EBTC should organize a number
of case studies to further demonstrate the value of evidence-based
approaches to toxicology. Such early “wins” are likely to be important in securing stakeholder buy-in early in the process.
A third theme, recurring throughout the workshop, was the
importance and challenge of transparency. Those carrying out
EBT reviews should strive to adhere scrupulously to the EBM
tenet of transparency. Yet EBT practitioners must cope with limits to transparency in toxicology, such as those imposed by data
confidentiality owing to corporate or regulatory policy. Any
challenges posed by practices within toxicology would be in addition to those plaguing other fields, such as the tendency not to
publish “no-effect” results (publication bias).
Fourth, the workshop repeatedly highlighted the fundamental
distinction between advocacy and analysis in the work of an
organization promoting evidence-based approaches. The Cochrane Collaboration confines its work in EBM/HC to analysis,
leaving advocacy to others who may decide to take up the results of Cochrane assessments and use them to promote changes
in healthcare policy. This issue echoes the distinction in toxicology between a test method’s assessment versus its regulatory
acceptance, with the idea that EBT could address the former
but regulators would make the judgment regarding acceptance.
Workshop participants seemed comfortable to have the EBTC
carry on the assessments-not-advocacy tradition as evidencebased approaches are translated from medicine to toxicology.
Finally, the workshop raised the important issue of who would
be interested in the output of the EBTC, i.e., who would be the
EBTC’s “customers.” The main end users of EBT reviews and
guidance will be diverse, including:
– Scientists interested in carrying out evidence-based reviews,
appraising the quality of published studies that they read, designing their own studies to high standards, and writing up
their own studies such that other scientists can better understand and replicate the details.
– Decision-makers in regulatory agencies responsible for approval of new chemicals or re-evaluation of existing chemicals, approval of new test methods, or the formulation of new
testing programs
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– Decision makers in industry responsible for the safety of new
chemicals being developed or existing chemicals already on
the market
– Scientists in government, industry, and academia involved in
developing and assessing new test methods
– Stakeholders in the NGO community interested in the intersection of toxicology and public health, environmental
health, and new test methods
Modernizing toxicological decision making and practices will
be especially relevant to regulators in government and scientists
in industry who are seeking to respond adequately to (i) regulatory drivers such as the REACH chemicals program in the EU
and the Endocrine Disruptor Screening Program in the US, (ii)
societal demands to move away from the current animal-based
testing methods, and (iii) the responsibility to test the enormous
backlog of poorly tested chemicals already in commerce. In
addition, technology developers have a financial stake in seeing that their innovations are assessed appropriately and implemented into practice.
7.3 Toxicological and organizational priorities
for the EBTC

Apart from the cross-cutting themes identified above, much of
the workshop focused on more specific topics related to the priorities that the EBTC might adopt. These discussions revolved
primarily around the issues of validation and governance.
7.3.1 Validation and evidence-based approaches

Much of the workshop program reflected the EBTC’s desire
to apply evidence-based approaches to assessing the performance of new test methods, especially the pathway-based assays
of 21st century toxicology. In this regard, the sessions provided
food for thought rather than specific advice.
In Session 1, Richard Judson presented a multi-authored
white paper that extensively discusses how the current validation framework might be adapted to the assessment of
high-throughput, pathway-based assays (Judson et al., 2013).
Validation is an assessment of an assay’s (or group of assays’)
reliability and relevance for a specific purpose. Judson focused
on the purpose (or “context of use”) of prioritizing chemicals
for later follow-up with more definitive, lower throughput testing. In this context, he argued that assessing relevance will be
a bigger challenge than assessing reliability, given the nature
of robotic, high-throughput systems. The white paper stresses
several themes that resonate with evidence-based approaches,
including transparency, continuous improvement, and data
quality. It also envisions the possibility of using evidence-based
approaches as a means of expanding the validation toolbox and
thereby offering an alternative to the current costly and timeconsuming validation framework, which is more suitable to
lower throughput methods.
Respondent Doug Wolf argued that a test method’s throughput should be key to determining whether its performance is
assessed with the current validation approach or a more EBTfocused approach, with lower throughput assays being assessed
via the former and higher throughput assays via the latter (Section 3.1).
Altex 30, 1/13

Regardless of the validation approach taken, respondent Ed
Carney agreed with Judson that validating high-throughput assays for the purpose of prioritizing chemicals for more definitive testing is a good place to start assessing their performance.
Similarly, assays with a well understood connection to adverse
outcomes, such as estrogen receptor binding, are good candidates to carry forward. Moreover, he noted the unexplored challenge of validating groups of complementary assays, rather than
single assays (Section 3.2).
In the workshop presentation by Grace Patlewicz and the
accompanying commentary by Patlewicz, Richard Becker, and
Ted Simon, these commentators, like Judson et al., mention
the possibility of carrying out a new generation of performance evaluations using evidence-based approaches (Section
3.3). They argue, however, for a somewhat different evaluation framework adapted from the Institute of Medicine report
on biomarkers, which emphasizes analytical validation, qualification, and utilization. Their preference for an approach that
involves qualification echoes Patricia Harlow’s description
of the U.S. FDA’s biomarker qualification program (Section
4.1).
While the speakers in Session 1 alluded to evidence-based
approaches being applied to the validation of high-throughput
assays, the ensuing open discussion began to sketch what that
process might look like in practice (Section 3.4). Its elements
would include defining the criteria up front, listing the candidate
chemicals, getting the planned procedure peer-reviewed prior
to execution, making adjustments, and then carrying out the revised procedure systematically.
Transparency would be key throughout, so the process could
not only be understood but also could be replicated by interested
parties. Establishing performance standards for a validated assay
or set of assays would facilitate the process of continuous improvement.
The overall aim of the process would be to establish the fitness for purpose of an assay by demonstrating its scientific basis. This is a type of relevance that is included, but not emphasized, in the current validation framework. It is a scientific or
mechanistic relevance, whereas the current framework focuses
on empiric relevance, i.e., correlation to results from reference
tests (Hartung, 2010).
The focus on test method validation as a suitable target for
EBT also predominated in Session 3, “Setting Priorities for
the Evidence-based Toxicology Collaboration.” In her presentation, Fitzpatrick noted that the new toxicology calls for new
approaches to validation, and that assessing fitness for purpose
should be tailored to different purposes depending on the relevant regulatory framework (see Section 5.1). Her presentation
(prepared with Abigail Jacobs) parallels Judson’s presentation
on mapping validation principles to the evaluation of highthroughput assays (Judson et al., 2013). Fitzpatrick’s perspective was that of a regulator, addressing the importance of incorporating the emerging methods of 21st century toxicology into
regulatory toxicology. She noted the inadequacy of the current
validation paradigm to assess the performance of pathway-based
assays and offered evidence-based approaches as a transparent
and structured way to move forward.
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The invited discussants and other commentators from Session 3 agreed with Fitzpatrick and Jacobs on using evidencebased approaches to assess the performance of pathway-based
assays as one of the goals of the EBTC (Sections 5.2-5.5).
Such assessments would be comparable to EBM’s assessments
of diagnostic tests and could be viewed as providing a kind of
quality assurance to the new toxicology’s emerging methods.
In keeping with the tenets of evidence-based approaches, these
assessments should be carried out in a transparent manner.
They also should involve diverse stakeholders. Multi-stakeholder assessments may be liable to reflect biases stemming
from differences in values and experiences but, fortunately,
evidence-based approaches are ideally suited to handle potential bias.
Workshop Sessions 1 and 3 highlighted the importance of
pathway-based testing and the need for new ways of assessing
the performance of such testing, with a clear call for mechanistic validation established through evidence-based means.
Two of the three presentations in Session 2 explored biological questions that will be central to mechanistic validation of
pathway-based methods. Daland Juberg addressed the issue
of distinguishing chemical effects that lead to adverse versus
adaptive changes in pathway-based assays (Keller et al., 2012).
This question is at the heart of the NRC vision of toxicology in
the 21st century (NRC, 2007). Similarly, Patricia Harlow addressed the evaluation of proposed biomarkers of biological effects, in the context of the biomarker qualification program of
the US FDA’s Center for Drug Evaluation and Research (see
Section 4.1). Once qualified and publicized, such biomarkers
can be pursued within their context of use as indicators of the
biological process in question, e.g., nephrotoxicity in rats, to
facilitate the drug development process. Assessing the performance of a proposed biomarker is comparable to making a diagnosis – how well does the biomarker in question diagnose or
predict the purposed effect. In her presentation, Harlow did not
go into the scientific details of the review of particular proposed
biomarkers, but she mentioned that the diagnostic performance
of urinary biomarkers for nephrotoxicity in rats was evaluated
by comparison with currently used nephrotoxicity markers using receiver operating characteristic (ROC) curves – a tool commonly used in EBM/HC assessments in diagnosis and likely to
feature prominently in the emerging EBT assessments of test
method performance.
The workshop also identified several other issues that will
need to be addressed when grappling with the validation of assays (high throughput or otherwise), whether by means of EBT
or not. These issues include the following:
– The proper focus of a validation exercise could be an individual assay or a group of complementary assays.
– The EBTC should not be perceived as biased in the outcome
of validation exercises, such as by giving the impression of
a hidden agenda in wanting to see animal-based methods replaced by in vitro methods.
– The EBTC may face the potential challenge of seeking to review the literature on the performance of emerging test methods that are so new that few studies have been published on
their performance.
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– Similarly much of the data on emerging test methods might
be in databases rather than published studies, so this would
require new approaches to assessment.
Judson suggested that the EPA EDSP might offer a good starting
point for an EBT analysis of pathway-based testing. One could
assess how well the proposed “EDSP21” assays can serve to
prioritize chemicals for testing in the tier-1 battery.
7.3.2 Governance and work processes

While workshop Sessions 1-3 primarily explored the nature
and scope of EBT and the types of toxicological questions
that the EBTC might address (especially the issue of assessing
test method performance), Session 4 explored how the newly
formed EBTC might organize itself and carry out its work to
pursue its mission efficiently.
In his presentation, John Fowle provided a comprehensive review of the issues that the EBTC should consider as it contemplates establishing a formal organizational structure and work
processes (see Section 6.1). He presented a detailed discussion
of the Cochrane Collaboration, which could serve as a model for
the EBTC to adopt and to adapt. Fowle’s more general advice
included the following: that the EBTC should strive to appeal to
hearts as well as minds, that it seek to achieve some short-term
wins to demonstrate its potential, and that it take the time to get
its governance and work processes right from the start (“going
slow to go fast”).
The invited discussants were complimentary of Fowle’s recommendations. There was general agreement on the issue of
looking to the Cochrane Collaboration as a model to draw organizational and administrative guidance from, as appropriate.
Roberta Scherer provided additional background information
on the Cochrane Collaboration (Section 6.2), whereas Rashid
Shaikh (Section 6.3) and Dennis Devlin (Section 6.4) discussed
the Health Effects Institute and Health and Environmental Sciences Institute, respectively, as additional organization models
that the EBTC could learn from. The final discussant, Andrew
Rowan, offered advice on a wide range of organizational issues
based on his experience in non-profit management and journal
editing (Section 6.5).
While addressing administrative issues may be tedious at
times, they are of paramount importance to the future success
of the EBTC. As Fowle pointed out, how well the EBTC addresses these issues could mean the difference between success
and failure in winning the hearts and minds of the hundreds of
volunteers that the EBTC is hoping to recruit to carry its important work forward. He noted that these issues may not seem like
priorities in the heady days of embarking on a new initiative, but
their importance warrants early attention.
Scherer’s presentation included historical remarks that provided a sense of how the Cochrane Collaboration grew and
evolved over time. Drawing on this experience should be helpful to the EBTC as it grapples with its administrative priorities
while evolving over time and seeking to strike the right balance
between subject-matter priorities and administrative ones.
Among the many key points made in the governance session
were the following:
– the importance of an organization’s mission and vision stateAltex 30, 1/13
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ments, of periodic strategic planning, and of distinguishing
the organization from similar groups;
– the challenges of administering an international organization;
– the sensitivity over accepting corporate funding for specific
projects;
– the importance of successful pilot projects to demonstrate
value, inspire confidence, motivate staff, and attract members and supporters;
– the need to clarify what EBT is and is not – If EBT applies
to all methods in toxicology, not just in vitro or 21st century
methods, and to all evidentiary-based questions in toxicology, not just those around validation, then this should be
stressed.
Thomas Hartung noted that some funding is available to support
the work of the EBTC as it moves forward on both sides of the
Atlantic. In addition to supporting the secretariat, this funding
could support workshops and small-scale studies.
7.4 Next steps for the EBTC

The US EBTC Steering Committee met one month after its
January 2012 workshop to consider the presentations, discussions, and recommendations from the workshop. The Steering
Committee is establishing work groups to address the emerging
toxicological, methodological, and organizational priorities for
EBT, many of which were identified at the workshop. For example, a methods work group will adapt the core EBM/HC-tools
to the toxicology context. This group also will develop tools
suitable for toxicological challenges that may not have close
parallels in clinical medicine, such as evidence-based appraisal
of data from heterogeneous types of studies (e.g., in vivo versus
in vitro).
Specifically, the methods work group will generate guidance
on topics such as information retrieval, data appraisal, evidence
synthesis, and test method assessment. The resulting prototype
guidance will need to be updated frequently as new insights are
gained from their applications.
In parallel, case study groups will explore how the guidance
is to be used in practice and how the tools perform by addressing the evaluation of either a test method (or test strategy) or
a health effect of a compound, or both scenarios. These studies are expected to demonstrate the feasibility of applying evidence-based approaches in toxicology and to underscore their
benefits as compared to standard practices. The components of
these evidence-based approaches will be completely transparent, allowing ready reproduction and identification of any bias,
e.g., the omission of data in a review. Ultimately, biases in toxicology – a widespread but largely disregarded aspect in the field
today – will be made amenable to assessment and exploration.
The EBTC also aims to further the conceptual development
of EBT and raise awareness of its principles and approaches.
The EBTC will evolve into an umbrella organization facilitating the application of evidence-based approaches to toxicology,
comparable to the role of the Cochrane Collaboration in EBM/
HC.22

7.5 Concluding remarks

The EBTC will seek to foster a growing interest in the application of evidence-based approaches in toxicology. The application of these new approaches is expected to strengthen the
scientific basis of decision making in toxicology and to improve
the transparency of research results, decision making, and the
reporting thereof. Better-structured publication of information
will facilitate evidence appraisal and synthesis when performing systematic reviews.
With respect to validation, adopting and adapting assessment
methodologies from medical diagnostics to toxicological tests
is expected to fertilize the development of highly relevant and
targeted toxicological testing methods and strategies. The use
of test methods based on human biology rather than animal/
rodent biology will bridge both the gap and the unquantifiable
uncertainty of inter-species differences. It is expected that new
technologies (biomarkers and -omics) can be more rapidly introduced as standard methods as evidence-based approaches
supplant the time-consuming and cumbersome validation procedures of today. In addition, frequent evidence-based reviews
of methods will help identify strengths and weaknesses of methods in practice, providing guidance for future improvements
and developments.
Bringing new approaches to the assessment of test method
performance will be particularly timely. As toxicology moves
to pathway-based approaches (as exemplified by the NRC report on Toxicity Testing in the 21st Century (NRC, 2007)), the
field will need new tools for assessing test method performance, especially as the focus shifts from animal to human biology. Similarly, as test methods are developed to assess effects
at multiple levels of biological organization (e.g., organ on a
chip), tools will be needed to synthesize such data in ways that
are transparent, objective, and systematic. Ultimately, this effort will open up new approaches to hazard and risk assessment with the ability to flexibly integrate new evidence or
adapt to it.
A modernized toxicology allowing transparent, objective, and
consistent decision making based on the best and latest available scientific evidence will increase confidence and trust of the
stakeholders in government, industry, academia, as well as NGOs
who have an interest in and are affected by these decisions.
Modernizing toxicological decision making and practices
will be especially relevant to those government regulators and
industry scientists who are striving to assess a backlog of inadequately tested chemicals, such as through the REACH program,
as well as to scientists in government, industry, and academia
who are seeking to implement pathway-based testing along the
lines proposed in the 2007 NRC report cited above. REACH
entails, among other components, a thorough assessment of
toxicological dossiers on individual chemicals, which is best
accomplished via an evidence-based approach. Pathway-based
testing is developing too rapidly to be amenable to current validation approaches; evidence-based approaches can fill this void,
especially where the reference standard shifts from high dose
animal studies to human biology.

22 http://www.cochrane.org
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The benefits of translating evidence-based approaches from
medicine to toxicology have been recognized since 2005. Experience since then has shown that this translation will not reach
a critical mass in practice unless interested stakeholders join together in a focused, well-funded effort. The January 2012 workshop was an important step in moving forward.
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